EP4218801A2 - Procédé de modification d'anticorps pour purifier un anticorps bispécifique - Google Patents

Procédé de modification d'anticorps pour purifier un anticorps bispécifique Download PDF

Info

Publication number
EP4218801A2
EP4218801A2 EP23150077.8A EP23150077A EP4218801A2 EP 4218801 A2 EP4218801 A2 EP 4218801A2 EP 23150077 A EP23150077 A EP 23150077A EP 4218801 A2 EP4218801 A2 EP 4218801A2
Authority
EP
European Patent Office
Prior art keywords
antibody
polypeptide
amino acid
humanized
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23150077.8A
Other languages
German (de)
English (en)
Other versions
EP4218801A3 (fr
Inventor
Tomoyuki Igawa
Hiroyuki Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP4218801A2 publication Critical patent/EP4218801A2/fr
Publication of EP4218801A3 publication Critical patent/EP4218801A3/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to methods of modifying antibodies for purification of bispecific antibodies, methods for separating the bispecific antibodies, and pharmaceutical compositions and such comprising the bispecific antibodies as active ingredients.
  • bispecific antibodies that can simultaneously recognize two types of antigens, e.g., antibody A and antibody B (see Non-Patent Document 1).
  • MDX-210 which is currently under clinical trial investigation, is an IgG-type bispecific antibody that retargets FcyRI-expressing monocytes and such to HER-2/neu-expressing cancer cells (see Non-Patent Document 2).
  • antibodies are produced using genetic recombination techniques.
  • One specific technique involves the cloning of a DNA encoding an antibody protein from antibody-producing cells, such as hybridomas or sensitized lymphocytes that produce antibodies or a phage library presenting antibody genes, and the insertion of such into a suitable vector, which is then transfected into host cells for antibody production.
  • Production of IgG type bispecific antibodies using genetic recombination techniques involves the introduction of a total of four types of genes into cells, in which these genes of H chains and L chains constitute two types of IgGs of interest, and the secretion of the antibodies by coexpression.
  • Non-Patent Document 3 and Non-Patent Document 4 the content of the chain A-chain B heterodimer of interest can be increased up to a maximum of about 95% as shown in Non-Patent Document 3 and Non-Patent Document 4, the remaining 5% is impurities and consists of chain A and chain B homodimers.
  • the chain A-chain B heterodimers must be purified to the highest possible purity from the three types of molecular species (chain A homodimer, chain B homodimer, and chain A-chain B heterodimer) that are produced when a common L chain is used (Non-Patent Document 3 and Non-Patent Document 4).
  • Non-Patent Document 5 reports a method for selectively purifying the chain A-chain B heterodimer using mouse IgG2a as chain A and rat IgG2b as chain B. This method uses difference between the respective mouse IgG2a and rat IgG2b H chains in their affinity for protein A, and purifies the chain A-chain B heterodimer by controlling the pH for elution from protein A.
  • this method since constant regions from mouse and rat are used, this method is difficult to apply to pharmaceuticals for human from the perspective of antigenicity. Furthermore, since this method cannot separate the chain A-chain B heterodimer, which is composed from H chains belonging to the same subclass, its use is limited.
  • Non-Patent Document 6 A method for purifying the chain A-chain B heterodimer using hydrophobic interaction chromatography is reported in Non-Patent Document 6.
  • the peak of the chain A-chain B heterodimer of interest containing anti-CD3 mouse IgG2a and anti-CD19 mouse IgG 1 is not sufficiently separated.
  • H chains belonging to different subclasses are used, and the difference in their hydrophobicity seems to be used for the separation.
  • this method may not necessarily separate the chain A-chain B heterodimer composed from H chains belonging to the same subclass.
  • Non-Patent Document 7 A method for purifying the chain A-chain B heterodimer using thiophilic affinity chromatography is reported in Non-Patent Document 7.
  • this method cannot be adopted to separate the chain A-chain B heterodimer composed from H chains belonging to the same subclass, because it uses mouse IgG1 and rat IgG2a, and the free cysteines (thiol groups) in the hinge regions.
  • this method is not suitable for development of stable pharmaceutical formulations.
  • Affinity chromatography using antigens is reported in Non-Patent Document 8.
  • affinity chromatography using proteins or peptide antigens is problematic in terms of cost and column stability, production of pharmaceuticals using affinity chromatography is unconventional.
  • affinity chromatography must be performed twice, and this is expected to become costly. It has been reported that there are antibodies that recognize only the three-dimensional structures of antigens as well as antibodies that have desired functions but low affinity. For antibodies with such characteristics, it is difficult to adopt affinity chromatography that uses antigens. Therefore, purification of bispecific antibodies using affinity chromatography cannot be used widely.
  • Non-Patent Document 9 since the amino acid sequence homology between antibody variable regions is very high (Non-Patent Document 9), it has been difficult to purify the chain A-chain B heterodimer to a high purity that is acceptable for pharmaceuticals solely based on the differences in their variable region sequences.
  • Carter P "Bispecific human IgG by design.”, J. Immunol. Methods., Feb 2001, Vol. 248(1-2), p.7-15 .
  • the present invention was achieved in view of the above circumstances.
  • An objective of the present invention is to provide methods for modifying the amino acids of antibody variable regions to efficiently purify bispecific antibodies, pharmaceutical compositions comprising the modified bispecific antibodies, and methods for producing the bispecific antibody pharmaceutical compositions.
  • Another objective of the present invention is to provide bispecific antibodies in which the heavy chain constant regions have been modified, pharmaceutical compositions comprising the modified bispecific antibodies, and methods for producing the bispecific antibody pharmaceutical compositions.
  • the present inventors conducted dedicated research on methods that substitute amino acids in antibody variable regions. These methods use a standard chromatography column to efficiently purify bispecific antibodies of interest which was conventionally challenging.
  • the present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points of the H chains of two types of antibodies, and the difference is introduced by modifying the amino acids present on the surface of the variable regions of the two types of antibodies that constitute a bispecific antibody. Specifically, the present inventors discovered sites of modification in the antibody H chain that enable regulation of the isoelectric point alone without reducing the antibody function (activity). Furthermore, the present inventors confirmed that bispecific antibodies obtained by the methods of the present invention actually maintain their functions.
  • the present inventors successfully developed methods for substituting amino acids in the antibody variable regions as efficient methods for purifying any bispecific antibody by using a standard chromatography column, and thereby completed the present invention.
  • the present inventors further devised methods to efficiently purify bispecific antibodies using a chromatography column based on the difference in isoelectric point. Constant regions of different subclasses originally having different isoelectric points are used as the constant regions of the two types of H chains that constitute a bispecific antibody. Furthermore, the present inventors confirmed that the bispecific antibodies obtained by the methods of the present invention actually maintain their functions.
  • the present invention relates to methods of substituting amino acids in the antibody variable regions for efficient purification by using a chromatography column, pharmaceutical compositions comprising the modified bispecific antibodies, and methods for producing the bispecific antibody pharmaceutical compositions.
  • the present invention also relates to bispecific antibodies in which the heavy chain constant regions have been modified, pharmaceutical compositions comprising the modified bispecific antibodies, and methods for producing the bispecific antibody pharmaceutical compositions. More specifically, the present invention relates to the following:
  • the present invention provides methods of modifying antibodies for production of multispecific antibodies.
  • a preferred embodiment of the production methods of the present invention is a method comprising modifying both or either one of a nucleic acid encoding the amino acid residues of a first polypeptide and a nucleic acid encoding the amino acid residues of a second polypeptide, so that the isoelectric points of the first polypeptide and second polypeptide will be different. That is, multispecific antibodies can be produced based on differences in isoelectric point (pI), and the difference can be introduced into polypeptides by altering the charges of the amino acid residues in the first polypeptide and second polypeptide. More specifically, a preferred production method comprises the following steps of
  • polypeptides generally refers to peptides and proteins whose length is approximately ten amino acids or longer. Polypeptides are generally derived from organisms, but are not particularly limited thereto, and for example, they may be composed of an artificially designed sequence. They may also be naturally derived polypeptides, synthetic polypeptides, recombinant polypeptides, or such. Additionally, fragments of the above-mentioned polypeptides are also included in the polypeptides of the present invention.
  • the phrase "the difference between the isoelectric points of the polypeptides" means that the isoelectric points of two or more polypeptides are made unequal by modifying the charges of the amino acids on the surface of each polypeptide.
  • the difference in the isoelectric points can be observed, for example, by using a technique such as isoelectric focusing.
  • the isoelectric points are preferably modified without altering the structure and/or function (activity) of the polypeptides.
  • the present invention provides a method for producing a multispecific antibody comprising a first polypeptide and a second polypeptide, wherein the method comprises the steps of
  • a preferred embodiment of the purification methods of the present invention is a method comprising the step of modifying both or either one of a nucleic acid encoding the amino acid residues of a first polypeptide and a nucleic acid encoding the amino acid residues of a second polypeptide, so that the isoelectric points of the first polypeptide and second polypeptide will be different. That is, the difference in isoelectric point (pI) is introduced into the polypeptides by altering the charges of the amino acid residues of the first polypeptide and those of the second polypeptide.
  • a purification method comprises the following steps of:
  • the nucleic acids of the present invention are generally cloned (inserted) into suitable vectors and then introduced into host cells. These vectors are not particularly limited so long as the inserted nucleic acids are stably maintained.
  • the cloning vectors are preferably pBluescript vectors (Stratagene) and such, while various commercially available vectors may be used.
  • expression vectors are particularly useful. There is no particular limitation on expression vectors, so long as they can express polypeptides in test tubes, E. coli, cultured cells, or individual organisms.
  • preferred vectors include pBEST vectors (Promega) for expression in test tubes, pET vectors (Invitrogen) in E . coli, the pME18S-FL3 vector (GenBank Accession No. AB009864) in cultured cells, and the pME18S vector ( Mol. Cell Biol. 8:466-472(1998 )) in individual rganisms. Insertion of the DNAs of the present invention into vectors can be performed, for example, by standard methods such as ligase reactions using restriction enzyme sites ( Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4-11.11 ).
  • Cells used for expressing polypeptides include bacterial cells (for example, Streptococcus, Staphylococcus, E. coli, Streptomyces, and Bacillus subtilis ) , fungal cells (for example, yeast and Aspergillus ) , insect cells (for example, Drosophila S2 and Spodoptera SF9), animal cells (for example, CHO, COS, HeLa, C127, 3T3, BHK, HEK293, Bowes melanoma cell), and plant cells.
  • bacterial cells for example, Streptococcus, Staphylococcus, E. coli, Streptomyces, and Bacillus subtilis
  • fungal cells for example, yeast and Aspergillus
  • insect cells for example, Drosophila S2 and Spodoptera SF9
  • animal cells for example, CHO, COS, HeLa, C127, 3T3, BHK, HEK293, Bowes melanoma cell
  • Vectors can be introduced into host cells using known methods, such as the calcium phosphate precipitation method, electroporation method ( Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9.1-9.9 ), lipofection method, and microinjection method.
  • known methods such as the calcium phosphate precipitation method, electroporation method ( Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9.1-9.9 ), lipofection method, and microinjection method.
  • suitable secretion signals can be incorporated into the polypeptides of interest. These signals may be intrinsic or foreign to the polypeptides of interest.
  • the multispecific antibodies (polypeptides) produced by the above-mentioned methods can be harvested by collecting the media.
  • the polypeptides of the present invention are produced inside cells, the cells first are lysed, and then these polypeptides are collected.
  • polypeptides of the present invention can be collected and purified from recombinant cell cultures using known methods, including ammonium sulfate or ethanol precipitation, acidic extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography.
  • compositions comprising a multispecific antibody of the present invention and a pharmaceutically acceptable carrier.
  • compositions generally refers to agents for treating or preventing, or testing and diagnosing diseases.
  • compositions of the present invention can be formulated by methods known to those skilled in the art.
  • such pharmaceutical compositions can be used parenterally in the form of injections, which are sterile solutions or suspensions prepared with water or another pharmaceutically acceptable liquid.
  • such compositions may be formulated by appropriately combining with a pharmaceutically acceptable carrier or medium, specifically, sterile water, physiological saline, vegetable oil, emulsifier, suspension, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, or such, and mixed in a unit dose form that meets the generally accepted requirements for preparation of pharmaceuticals.
  • the amount of active ingredient is adjusted such that a suitable amount within a specified range is obtained.
  • Sterile compositions for injection can be formulated using vehicles such as distilled water for injection, according to standard protocols for formulation.
  • Aqueous solutions for injection include, for example, physiological saline and isotonic solutions containing glucose or other adjuvants (for example, D-sorbitol, D-mannose, D-mannitol, and sodium chloride).
  • glucose or other adjuvants for example, D-sorbitol, D-mannose, D-mannitol, and sodium chloride.
  • Appropriate solubilizers for example, alcohols (ethanol and such), polyalcohols (propylene glycol, polyethylene glycol, and such), non-ionic surfactants (polysorbate 80 TM , HCO-50, and such) may be used in combination.
  • Oils include sesame and soybean oils.
  • Benzyl benzoate and/or benzyl alcohol can be used as solubilizers in combination.
  • Buffers for example, phosphate buffer and sodium acetate buffer
  • soothing agents for example, procaine hydrochloride
  • stabilizers for example, benzyl alcohol and phenol
  • antioxidants can also be combined. Prepared injections are generally filled into appropriate ampules.
  • compositions of the present invention are preferably administered parenterally.
  • the compositions may be in the form of injections, transnasal agents, transpulmonary agents, or transdermal agents.
  • such compositions can be administered systemically or locally by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, or such.
  • the administration methods can be appropriately selected in consideration of a patient's age and symptoms.
  • the dosage of a pharmaceutical composition comprising an antibody or a polynucleotide encoding an antibody may be set, for example, within the range of 0.0001 to 1000 mg/kg weight for each administration. Alternatively, the dosage may be, for example, from 0.001 to 100,000 mg per patient. However, in the present invention, the dosage is not necessarily limited to the ranges described above. Although the dosage and administration method vary depending on a patient's weight, age, symptoms, and such, those skilled in the art can select appropriate dosage and administration methods in consideration of the factors described above.
  • the multispecific antibodies of the present invention can be formulated by combining with other pharmaceutical components as necessary.
  • the present invention also provides nucleic acids encoding polypeptides that constitute the multispecific antibodies of the present invention. Furthermore, vectors that carry these nucleic acids are also included in the present invention.
  • the present invention also provides host cells carrying the above described nucleic acids.
  • the host cells are not particularly limited and include, for example, E coli and various animal cells.
  • the host cells may be used, for example, as a production system to produce and express the antibodies or polypeptides of the present invention.
  • Eukaryotic cells that can be used as host cells include, for example, animal cells, plant cells, and fungal cells.
  • Animal cells include: mammalian cells, for example, CHO (J. Exp. Med. (1995) 108, 945 ), COS, HEK293, 3T3, myeloma, BHK (baby hamster kidney), HeLa, and Vero; amphibian cells such as Xenopus laevis oocytes ( Valle, et al., Nature (1981) 291: 338-340 ); and insect cells such as Sf9, Sf21, and Tn5.
  • mammalian cells for example, CHO (J. Exp. Med. (1995) 108, 945 ), COS, HEK293, 3T3, myeloma, BHK (baby hamster kidney), HeLa, and Vero
  • amphibian cells such as Xenopus laevis oocytes ( Valle, et al., Nature (1981)
  • CHO-DG44 For expressing the antibodies of the present invention, CHO-DG44, CHO-DX11B, COS7 cells, HEK293 cells, and BHK cells can be suitably used. Of the animal cells, CHO cells are particularly preferable for large-scale expression.
  • Vectors can be introduced into a host cell by, for example, calcium phosphate methods, DEAE-dextran methods, methods using cationic liposome DOTAP (Boehringer-Mannheim), electroporation methods, or lipofection methods.
  • plant cells such as Nicotiana tabacum-derived cells and Lemna minor cells are protein production systems, and these cells can be used to produce antibodies of the present invention by methods that culture calluses from these cells.
  • Protein expression systems that use fungal cells including yeast cells, for example, cells of the genus Saccharomyces ( Saccharomyces cerevisiae, Saccharomyces pombe, etc.), and cells of filamentous fungi, for example, the genus Aspergillus ( Aspergillus niger, etc.) are known, and these cells can be used as a host to produce antibodies of the present invention.
  • prokaryotic cells When prokaryotic cells are used, production systems that use bacterial cells are available. Production systems that use bacterial cells including Bacillus subtilis as well as E . coli described above are known, and they can be used to produce antibodies of the present invention.
  • a polynucleotide encoding an antibody of the present invention may be expressed by culturing the host cell transformed with an expression vector comprising the polynucleotide. Culturing can be performed according to known methods. For example, when animal cells are used as a host, DMEM, MEM, RPMI 1640, or IMDM may be used as the culture medium. The culture medium may be used with serum supplement solutions such as FBS or fetal calf serum (FCS). Alternatively, cells can be cultured in serum-free cultures. The preferred pH is about 6 to 8 during the course of culturing. Incubation is carried out typically at about 30 to 40°C for about 15 to 200 hours. Medium is exchanged, aerated, or agitated, as necessary.
  • systems for producing polypeptides in vivo include, for example, those using animals and those using plants.
  • a polynucleotide of interest is introduced into an animal or plant to produce the polypeptide in the body of the animal or the plant, and then the polypeptide is collected.
  • the "host" of the present invention includes such animals and plants.
  • mammals When animals are used, production systems that use mammals or insects are available. Mammals such as goat, pig, sheep, mouse, and cattle may be used ( Vicki Glaser, SPECTRUM Biotechnology Applications (1993 )). When mammals are used, transgenic animals may be used.
  • a polynucleotide encoding a antibody of the present invention may be prepared as a fusion gene with a gene encoding a polypeptide specifically produced in milk, such as goat ⁇ -casein.
  • polynucleotide fragments containing this fusion gene are injected into goat embryos, which are then introduced back into female goats.
  • the antibody of interest can be obtained from milk produced by the transgenic goats, which are born from the goats that received the embryos, or by their offspring.
  • Appropriate hormones may be administered to the transgenic goats to increase the volume of milk containing the antibody produced by the transgenic goats ( Ebert et al., Bio/Technology (1994) 12: 699-702 ).
  • Insects such as silkworms may be used for producing antibodies of the present invention.
  • silkworms When silkworms are used, baculoviruses carrying a polynucleotide encoding an antibody of interest can be used to infect silkworms, so that the antibody of interest can be obtained from the body fluids of these silkworms ( Susumu et al., Nature (1985) 315:592-594 ).
  • Plants used for producing antibodies of the present invention include, for example, tobacco.
  • a polynucleotide encoding an antibody of interest is inserted into a plant expression vector, for example, pMON 530, and then the vector is introduced into a bacterium such as Agrobacterium tumefaciens.
  • the bacteria are then used to infect tobacco such as Nicotiana tabacum, and the desired antibody can be obtained from the leaves of the tobacco ( Ma et al., Eur. J. Immunol. (1994) 24: 131-138 ).
  • the same bacteria can be used to infect Lemna minor, and after cloning, the desired antibody can be obtained from the cells of Lemna minor ( Cox K.M. et al., Nat. Biotechnol. 2006 Dec; 24(12):1591-1597 ).
  • the antibody thus obtained may be isolated from the inside or outside (such as the medium and milk) of host cells, and purified as a substantially pure and homogenous antibody. Methods used for separating and purifying an antibody are not limited, and methods used in standard polypeptide purification may be applied. Antibodies may be isolated and purified by selecting an appropriate combination of, for example, chromatographic columns, filtration, ultrafiltration, salting-out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, and such.
  • Chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and adsorption chromatography ( strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., (1996) Cold Spring Harbor Laboratory Press ). These chromatographies can be carried out using liquid phase chromatography such as HPLC and FPLC. Examples of columns for affinity chromatography include protein A columns and protein G columns. Examples of the columns that use protein A include Hyper D, POROS, and Sepharose F. F. (Pharmacia).
  • An antibody can be modified arbitrarily, and peptides can be deleted partially from the antibody by treatment with an appropriate protein modifying enzyme before or after antibody purification, as necessary.
  • protein modifying enzymes include, for example, trypsins, chymotrypsins, lysyl endopeptidases, protein kinases, and glucosidases.
  • Another preferred embodiment of the present invention includes a method for producing a multispecific antibody of the present invention, wherein the method comprises the steps of culturing the host cells of the present invention as described above and collecting the polypeptide from the cell culture.
  • multispecific antibody refers to an antibody that can specifically bind to at least two different types of antigens.
  • preferred multispecific antibodies obtained by the production methods or purification methods of the present invention include bispecific antibodies (BsAbs) (also called dual-specificity antibodies) that can specifically bind to two antigens.
  • BsAbs bispecific antibodies
  • dual-specificity antibodies also called dual-specificity antibodies
  • the term "different antigens” does not necessarily mean that the antigens themselves are different, and may mean that the epitopes are different. Therefore, for example, different epitopes within a single molecule are also included in the "different antigens" of the present invention.
  • two antibodies that recognize different epitopes within a single molecule are regarded as antibodies that recognize different antigens.
  • the multispecific antibodies of the present invention are antibodies having specificity to two or more different antigens, or molecules comprising fragments of such antibodies.
  • the phrase "modification of nucleic acids” comprises modification of nucleic acids that results in separated peaks of a first polypeptide and a second polypeptide by standard chromatography analysis.
  • the phrase "modification of nucleic acids” refers to modifying nucleic acids that correspond to the amino acid residues that are introduced by “modification” of the present invention. More specifically, the phrase refers to altering nucleic acids encoding the original amino acid residues (before modification) to nucleic acids encoding amino acid residues that are introduced by the modification.
  • the phrase means gene manipulation or mutagenesis that modifies the original nucleic acids by inserting, deleting, or substituting at least one nucleotide, to produce a codon that encodes an amino acid residue of interest More specifically, a codon encoding the original amino acid residue is replaced by a codon encoding the amino acid residue to be introduced by the modification.
  • nucleic acid modifications can be carried out appropriately by those skilled in the art using known techniques, for example, site-directed mutagenesis or PCR mutagenesis.
  • the modification positions in the present invention include, for example, (1) amino acid residues on the surface of a polypeptide, (2) amino acid residues in the variable region, preferably in the FR region, and (3) amino acid residues in the constant region.
  • amino acids on the surface of a polypeptide are amino acids whose side chains can contact solvent molecules (usually water molecules). It is not necessary for the entire side chain to be in contact with solvent molecules, and even if only part of the side chain is in contact with solvent molecules, the amino acid is considered to be an amino acid on surface.
  • solvent molecules usually water molecules.
  • the amino acid is considered to be an amino acid on surface.
  • Those skilled in the art can produce homology models of polypeptides or antibodies by homology modeling and such using commercially available software, and thereby selecting appropriate residues as amino acids on the surface.
  • Those skilled in the art can suitably select surface amino acids in the antibody variable region using homology models produced by homology modeling and such.
  • H1, H3, H5, H8, H10, H12, H13, H15, H16, H19, H23, H25, H26, H39, H42, H43, H44, H46, H68, H71, H72, H73, H75, H76, H81, H82b, H83, H85, H86, H105, H108, H110, and H112 are examples of surface amino acids.
  • the surface amino acids of the present invention are not limited thereto.
  • surface amino acids can be similarly selected using homology models.
  • L1, L3, L7, L8, L9, L11, L12, L16, L17, L18, L20, L22, L38, L39, L41, L42, L43, L45, L46, L49, L57, L60, L63, L65, L66, L68, L69, L70, L74, L76, L77, L79, L80, L81, L85, L100, L103, L105, L106, L107, and L108 are examples of surface amino acids.
  • the surface amino acids of the present invention are not limited thereto.
  • surface amino acids can be similarly selected using homology models.
  • amino acid residues in the variable region include amino acid residues in the heavy chain variable region (VH) or light chain variable region (VL), and are preferably amino acid residues in the framework region (FR).
  • surface-exposed amino acids other than those in CDR are, for example, H10, H12, H23, H39, H43, and H105 in the FR region, but are not limited thereto.
  • polypeptides with nucleic acid modification are preferably a homomultimer of a first polypeptide, a homomultimer of a second polypeptide, and a heteromultimer of the first polypeptide and second polypeptide.
  • the homomultimer of a first polypeptide is, for example, a homodimer of the humanized A69-H chain and humanized BBA-L chain
  • a homomultimer of a second polypeptide is, for example, a homodimer of the humanized B26-H chain and humanized BBA-L chain
  • a heteromultimer of a first polypeptide and a second polypeptide is, for example, a heterodimer of the humanized A69-H chain, humanized B26-H chain, and humanized BBA-L chain.
  • the polypeptides are not limited thereto.
  • Examples of standard chromatography in the present invention include cation exchange chromatography, anion exchange chromatography, hydrophobic chromatography, hydroxyapatite chromatography, hydrophobic charge interaction chromatography, and chromatofocusing.
  • a first polypeptide and a second polypeptide preferably comprise a heavy chain variable region (VH).
  • the variable region may comprise, for example, a complementary determining region (CDR) and a framework region (FR).
  • the number of amino acid residues that undergo modification in the methods of the present invention is not particularly limited. However, for example, when the variable region(s) of an antibody is modified, it is preferable that for the separation of polypeptides of interest, the number of modified amino acid residues be kept to the minimum as necessary, so as not to decrease the antigen binding activity or increase the antigenicity of the antibody.
  • the amino acid sequences after modification in the present invention are preferably human sequences, but are not limited thereto. Furthermore, in order to turn each of the modified FRs (FR1, FR2, FR3, and FR4) into a human sequence, mutations may be introduced into positions other than those that have been modified for alteration of isoelectric point. The method of replacing each FR with a human sequence in this manner has been reported in a Non-Patent Document ( Ono K. et al., Mol. Immunol. 1999 Apr; 36(6):387-395 ).
  • the FR can be modified into another human FR having a different isoelectric point (for example, FR3 can be replaced with another human FR having a lower isoelectric point).
  • FR3 can be replaced with another human FR having a lower isoelectric point.
  • the desired multispecific antibody can be obtained by repeating modification of surface charge and evaluation of polypeptide separation.
  • a multispecific antibody preferably comprises a third polypeptide comprising a light chain variable region, and preferably, the first polypeptide and the second polypeptide each forms a multimer with the third polypeptide.
  • a first polypeptide and a second polypeptide preferably comprise a heavy chain constant region that preferably generates different pIs for the first polypeptide and second polypeptide.
  • heavy chain constant regions include heavy chain constant regions of antibodies having different pIs.
  • the pI difference can be introduced into the first polypeptide and the second polypeptide using the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4 which have pIs that are originally different from each other.
  • amino acids in the heavy chain constant regions of the first polypeptide and the second polypeptide that cause differences in isoelectric point among these subclasses can be modified alone, or in combination with adjacent amino acids that do not have any effect on the isoelectric points to generate non-wild-type human constant regions, and pI difference can be introduced into the two constant regions.
  • positions to be modified for introducing pI difference into the constant regions include, for example, positions 137, 196, 203, 214, 217, 233, 268, 274, 276, 297, 355, 392, 419, and 435, EU numbering, in the H chain constant region.
  • position 297 which is a glycosylated site
  • position 297 is another example of a position to be modified for introducing pI difference.
  • methods that comprise the above-mentioned first polypeptide and second polypeptide comprising a heavy chain constant region methods that combine with the method in which the above-mentioned first polypeptide and second polypeptide comprise a heavy chain variable region, and/or the method in which the multispecific antibody comprises a third polypeptide comprising a light chain variable region, and a first polypeptide and a second polypeptide that each forms a multimer with the third polypeptide, are included in the present invention.
  • Multispecific antibodies produced by the above-mentioned methods are also included in the present invention.
  • the first polypeptide in the multispecific antibody provided by the present invention comprises a heavy chain variable region and/or a heavy chain constant region
  • at least one amino acid residue in the region is made to carry a charge so that "the isoelectric points will be different".
  • the amino acid residue(s) is selected from amino acid residues at positions 10, 12, 23, 39, 43, and 105, Kabat numbering, in the heavy chain variable region, or amino acid residues at positions 137, 196, 203, 214, 217, 233, 268, 274, 276, 297, 355, 392, 419, and 435, EU numbering, in the heavy chain constant region.
  • amino acid residues other than the charged amino acid residue may have the same type of charge as that of the charged amino acid residue, or may be uncharged, or may have the opposite charge of that of the charged amino acid residue, as long as the isoelectric point of the first polypeptide and that of the second polypeptide are different.
  • the above-mentioned multispecific antibodies of the present invention comprise a second polypeptide that preferably has the opposite charge of that of the charged amino acid residue in the first polypeptide, or is uncharged. More specifically, the second polypeptide in the multispecific antibodies comprises a heavy chain variable region and/or a heavy chain constant region, and at least one amino acid residue in the region is uncharged or has the opposite charge of that of the amino acid residue selected to carry a charge in the heavy chain variable region and/or the heavy chain constant region in the first polypeptide.
  • amino acid residue(s) is selected from amino acid residues at positions 10, 12, 23, 39, 43, and 105, Kabat numbering, in the heavy chain variable region, or amino acid residues at positions 137, 196, 203, 214, 217, 233, 268, 274, 276, 297, 355, 392, 419, and 435, EU numbering, in the heavy chain constant region.
  • amino acid residues other than the charged amino acid residue may have the same type of charge as that of the charged amino acid residue, or may be uncharged, or may have the opposite charge of that of the charged amino acid residue, as long as the isoelectric point of the first polypeptide and that of the second polypeptide are different.
  • an IgG2 or IgG4 sequence to position 137 an IgG1, IgG2, or IgG4 sequence to position 196, an IgG2 or IgG4 sequence to position 203, an IgG2 sequence to position 214, an IgG1, IgG3, or IgG4 sequence to position 217, an IgG1, IgG3, or IgG4 sequence to position 233, an IgG4 sequence to position 268, an IgG2, IgG3, or IgG4 sequence to position 274, an IgG1, IgG2, or IgG4 sequence to position 276, an IgG4 sequence to position 355, an IgG3 sequence to position 392, an IgG4 sequence to position 419, and an IgG1, IgG2, or IgG4 sequence to position 435.
  • an IgG1 or IgG3 sequence to position 137 an IgG3 sequence to position 196, the IgG1 or IgG3 sequence to position 203, an IgG1, IgG3, or IgG4 sequence to position 214, an IgG2 sequence to position 217, an IgG2 sequence to position 233, an IgG1, IgG2, or IgG3 sequence to position 268, an IgG1 sequence to position 274, an IgG3 sequence to position 276, an IgG1, IgG2, or IgG3 sequence to position 355, an IgG1, IgG2, or IgG4 sequence to position 392, an IgG1, IgG2, or IgG3 sequence to position 419, and an IgG3 sequence to position 435.
  • amino acids are known to be charged amino acids.
  • lysine (K), arginine (R), and histidine (H) are known as positively charged amino acids (cationic amino acids).
  • Aspartic acid (D), glutamic acid (E), and such are known as negatively charged amino acids (anionic amino acids).
  • charged amino acid residues are suitably selected from amino acid residues included in either one of groups (a) and (b) below, but are not particularly limited thereto:
  • the phrase "having the same type of charge” means, for example, that the above-mentioned amino acid residue in the heavy chain variable region according to Kabat numbering and the above-mentioned amino acid residue in the heavy chain constant region according to EU numbering both carry an amino acid residue included in either one of the above-mentioned groups (a) and (b).
  • phrases, "having the opposite charge” means that, for example, at least one of the above-mentioned amino acid residues, by Kabat numbering or EU numbering, in the second polypeptide comprising a heavy chain variable region and/or a heavy chain constant region is included in either one of the above-mentioned groups (a) or (b), and its corresponding amino acid residue at a position in the heavy chain variable region and/or heavy chain constant region comprised in the first polypeptide is included in the other group.
  • the present invention provides multispecific antibodies, in which the above-mentioned amino acid residues having the same type of charge are selected from the amino acid residues included in either one of the above-mentioned group (a) or (b).
  • the original amino acid residue (before modification) if it is already charged, it may be modified to be an uncharged amino acid residue.
  • an amino acid residue is preferably modified such that the isoelectric point (pI) of the first polypeptide and that of the second polypeptide will be different. Furthermore, when multiple amino acid residues are introduced by modification, a few uncharged amino acid residues may be included in these amino acid residues.
  • variable region of the first polypeptide comprises the amino acid sequence of any one of (a1) to (a7) below
  • variable region of the second polypeptide comprises the amino acid sequence of any one of (b)1 to (b3) below
  • variable region of the third polypeptide comprises the amino acid sequence of (c1) or (c2) below:
  • amino acids are specific examples of the amino acids subjected to modification in the present invention.
  • variable regions are not limited to those comprising these amino acids.
  • variable region of the first polypeptide comprises the amino acid sequence of SEQ ID NO: 11
  • variable region of the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16
  • variable region of the third polypeptide comprises the amino acid sequence of SEQ ID NO: 17.
  • variable region of the first polypeptide comprises the amino acid sequence of SEQ ID NO: 12
  • variable region of the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16
  • variable region of the third polypeptide comprises the amino acid sequence of SEQ ID NO: 18.
  • a further preferred embodiment of the above-mentioned multispecific antibody is a multispecific antibody, wherein the first polypeptide and the second polypeptide comprise the human IgG4 constant region, and wherein the third polypeptide comprises the human ⁇ constant region.
  • antibody is used in the broadest sense, and includes monoclonal antibodies, polyclonal antibodies, and mutant antibodies, such as chimeric antibodies, humanized antibodies, minibodies (including antibody fragments), and multispecific antibodies, as long as they display a desired biological activity.
  • the methods of antibody modification of the present invention can be used favorably on these antibodies when they are obtained (produced).
  • the "antibodies" of the present invention include antibodies in which the charge of amino acid residues has been modified as described above, and whose amino acid sequences have been further modified by amino acid substitutions, deletions, additions, and/or insertions.
  • the antibodies also include antibodies whose amino acid sequences have been modified by amino acid substitution, deletion, addition, and/or insertion, or chimerization, humanization, or such, and in which the charge of amino acid residues has been further modified. In short, modifications may be performed at the same time when mouse antibodies are humanized, or further modifications may be performed on humanized antibodies.
  • amino acid sequence modifications such as amino acid substitutions, deletions, additions, and/or insertions, and humanization and chimerization, can be achieved by methods known to those skilled in the art.
  • the amino acid sequences of the antibody variable and constant regions may also be modified by amino acid substitutions, deletions, additions, and/or insertions, or chimerization, humanization and the like.
  • the antibodies of the present invention may be derived from any animal, such as a mouse, human, rat, rabbit, goat, or camel. Furthermore, the antibodies may be modified, for example, chimeric antibodies, and in particular, modified antibodies that include amino acid substitutions in their sequence, such as humanized antibodies.
  • the antibodies may be any type of antibody, such as antibody modification products linked with various molecules, antibody fragments, and minibodies.
  • Chimeric antibodies are antibodies prepared by combining sequences derived from different animals.
  • An example is an antibody having heavy and light chain variable (V) regions from a mouse antibody and heavy and light chain constant (C) regions from a human antibody.
  • Chimeric antibodies can be prepared by known methods. To obtain such chimeric antibodies, for example, a DNA encoding an antibody V region may be ligated with a DNA encoding a human antibody C region; the resulting ligation product can be inserted into an expression vector; and the construct can be introduced into a host to produce the chimeric antibody.
  • Humanized antibodies are also referred to as reshaped human antibodies, and can be obtained by substituting the complementary determining region (CDR) of a human antibody for the CDR of an antibody derived from a nonhuman mammal, for example, a mouse.
  • CDR complementary determining region
  • Methods for identifying CDRs are known in the art ( Kabat et al., Sequence of Proteins of Immunological Interest (1987), National Institute of Health, Bethesda, Md .; Chothia et al., Nature (1989) 342:877 ).
  • General genetic recombination techniques suitable for this purpose are also known (see European Patent Application EP 125023 ; and WO 96/02576 ).
  • the CDR of a mouse antibody can be determined by known methods, and a DNA can be prepared such that it encodes an antibody in which the CDR is ligated with the framework region (FR) of a human antibody.
  • a humanized antibody can then be produced using a system that uses conventional expression vectors.
  • DNAs can be synthesized by PCR, using as primers several oligonucleotides designed to include portions that overlap the ends of both the CDR and FR regions (see the method described in WO 98/13388 ).
  • Human antibody FRs linked via CDRs are selected such that the CDRs form a suitable antigen binding site.
  • amino acids in the FRs of an antibody variable region may be substituted so that the CDRs of the reshaped human antibody can form a suitable antigen binding site ( Sato, K. et al., Cancer Res. (1993) 53:851-856 ).
  • Modifiable amino acid residues in the FRs include portions that directly bind to an antigen via non-covalent bonds ( Amit et al., Science (1986) 233: 747-53 ), portions that have some impact or effect on the CDR structure ( Chothia et al., J. Mol. Biol. (1987) 196: 901-17 ), and portions involved in the interaction between VH and VL ( EP 239400 ).
  • the C regions of these antibodies are preferably derived from human antibodies.
  • C ⁇ 1, Cy2, Cy3, and C ⁇ 4 can be used for the H chain, while C ⁇ and C ⁇ can be used for the L chain.
  • the human antibody C region may be modified as required to improve antibody or production stability.
  • a chimeric antibody of the present invention preferably includes a variable region of an antibody derived from a nonhuman mammal and a constant region of a human antibody.
  • a humanized antibody preferably includes CDRs of an antibody derived from a nonhuman mammal and FRs and C regions of a human antibody.
  • the constant regions of the human antibodies include specific amino acid sequences, which vary depending on the isotype of the antibody, for example, IgG (IgG1, IgG2, IgG3, and IgG4), IgM, IgA, IgD, and IgE.
  • the constant regions used to prepare the humanized antibodies of the present invention may be the constant regions of antibodies of any isotype.
  • a constant region of human IgG is preferably used, although the invention is not limited thereto.
  • the FRs derived from a human antibody, which are used to prepare the humanized antibodies, are not particularly limited, and thus may be derived from an antibody of any isotype.
  • variable and constant regions of chimeric or humanized antibodies of the present invention may be modified by deletion, substitution, insertion, and/or addition, so long as the antibodies exhibit the same binding specificity as that of the original antibodies.
  • minibodies are useful as the antibodies because of their in vivo kinetic characteristics and low-cost production using E. coli, plant cells, or such.
  • Antibody fragments are one type of minibody.
  • minibodies includes antibodies that include an antibody fragment as a partial structural unit.
  • the minibodies of the present invention are not particularly limited by their structure nor their method of production, so long as they have antigen binding activity. Some minibodies have an activity greater than that of a whole antibody ( Orita et al., Blood (2005) 105:562-566 ).
  • the "antibody fragments” are not particularly limited, so long as they are a portion of a whole antibody (for example, whole IgG).
  • the antibody fragments preferably include a heavy chain variable region (VH) or a light chain variable region (VL).
  • Examples of preferred antibody fragments are: Fab, F(ab') 2 , Fab', and Fv.
  • the amino acid sequence of a VH or VL in an antibody fragment may be modified by substitution, deletion, addition, and/or insertion. Furthermore, some portions of a VH and VL may be deleted, so long as the resulting fragments retain their antigen binding ability.
  • Fv is a minimal antibody fragment composed of the complete antigen recognition and binding sites.
  • “Fv” is a dimer (VH-VL dimer) composed of one unit of VH and one unit of VL bound very strongly by non-covalent bonding.
  • variable region An antigen binding site is formed on the surface of the VH-VL dimer by the three complementary determining regions (CDRs) of each variable region.
  • CDRs complementary determining regions
  • Six CDRs confer an antigen binding site to the antibody.
  • one variable region or half of an Fv composed of only three antigen-specific CDRs
  • molecules smaller than Fv are also included in the context of antibody fragments of the present invention.
  • the variable regions of an antibody fragment may also be chimerized or humanized.
  • the minibodies preferably include both VH and VL.
  • suitable minibodies include antibody fragments such as Fab, Fab', F(ab')2, and Fv, and scFv (single-chain Fv), which can be prepared using antibody fragments, ( Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85: 5879-83 ; Pluckthun "The Pharmacology of Monoclonal Antibodies” Vol. 113, Resenburg and Moore (eds.), Springer Verlag, New York, pp. 269-315, (1994 )); diabodies ( Holliger et al., Proc. Natl. Acad. Sci.
  • An antibody fragment can be prepared by treating an antibody with an enzyme, for example, a protease such as papain or pepsin (see Morimoto et al., J. Biochem. Biophys. Methods (1992) 24: 107-17 ; Brennan et al., Science (1985) 229:81 ).
  • an enzyme for example, a protease such as papain or pepsin (see Morimoto et al., J. Biochem. Biophys. Methods (1992) 24: 107-17 ; Brennan et al., Science (1985) 229:81 ).
  • antibody fragments can also be produced by genetic recombination based on its amino acid sequence.
  • a minibody having a structure that results from modification of an antibody fragment can be prepared using antibody fragments obtained by enzyme treatment or genetic recombination.
  • the minibody may be expressed in appropriate host cells (see, for example, Co et al., J. Immunol. (1994) 152: 2968-76 ; Better and Horwitz, Methods Enzymol. (1989) 178: 476-96 ; Pluckthun and Skerra, Methods Enzymol. (1989) 178: 497-515 ; Lamoyi, Methods Enzymol. (1986) 121: 652-63 ; Rousseaux et al., Methods Enzymol. (1986) 121: 663-9 ; Bird and Walker, Trends Biotechnol. (1991) 9: 132-7 ).
  • scFVs are single-chain polypeptides that include two variable regions linked together via a linker or such, as required.
  • the two variable regions in an scFv are typically one VH and one VL, but an scFv may include two VH or two VL.
  • scFv polypeptides include a linker between the VH and VL domains, thereby forming a paired portion of VH and VL required for antigen binding.
  • a peptide linker composed of ten or more amino acids is typically used as the linker between VH and VL when forming an intramolecular paired portion between VH and VL.
  • linkers of the scFv of the present invention are not limited to such peptide linkers, so long as they do not inhibit the formation of an scFv.
  • diabodies refers to bivalent antibody fragments constructed by gene fusion ( P. Holliger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993 ); EP 404,097 ; WO93/11161 and such).
  • Diabodies are dimers composed of two polypeptide chains, wherein each polypeptide chain includes within the same chain a light chain variable region (VL) and a heavy chain variable region (VH) connected with a linker short enough to disable interaction of these two regions, for example a linker of about five amino acid residues.
  • VL and VH encoded on the same polypeptide chain will form a dimer because the linker between VL and VH is too short to form a single chain V region fragment. Therefore, the resulting diabody has two antigen-binding sites.
  • VL and VH directed against two different epitopes (a and b) are expressed simultaneously as combinations of VLa-VHb and VLb-VHa connected with a linker of about five residues, they are secreted as bispecific Db.
  • diabodies include two molecules of scFvs, they thus composed of four variable regions, and as a result have two antigen binding sites.
  • linkers forming a connection between VH and VL in each scFv molecules are linkers of about five amino acids when used as peptide linkers.
  • scFv linkers for diabody formation are not limited to such peptide linkers so long as they do not interfere with scFv expression and diabody formation.
  • an example of a multispecific antibody is a bispecific antibody.
  • bispecific antibody may be, for example, an antibody having a structure in which a heavy chain variable region and a light chain variable region are linked in a single chain (for example, sc(Fv)2).
  • the bispecific antibody may also be an antibody-like molecule (for example, scFv-Fc) produced by fusing an scFv (or sc(Fv)2), in which a heavy chain variable region and a light chain variable region are linked, to an Fc region (a constant region lacking the CH1 domain).
  • a multispecific antibody consisting of scFv-Fc has an (scFv)2-Fc type structure with VH1-linker-VL1-Fc as the first polypeptide and VH2-linker-VL2-Fc as the second polypeptide.
  • the bispecific antibody may be an antibody-like molecule in which a single domain antibody is linked with an Fc region ( Curr. Opin. Drug Discov. Devel. 2006, 9(2), 184-93 ).
  • an antibody of the present invention known sequences can be used, or they can be obtained by methods known to those skilled in the art. For example, they may be obtained from an antibody library, or they may be obtained by cloning genes encoding the antibody from hybridomas producing monoclonal antibodies.
  • antibody libraries many antibody libraries are already well known, and since methods for producing antibody libraries are known, those skilled in the art can appropriately obtain antibody libraries.
  • antibody phage libraries one can refer to the literature such as Clackson et al., Nature 1991, 352: 624-8 ; Marks et al., J. Mol. Biol. 1991, 222: 581-97 ; Waterhouses et al., Nucleic Acids Res. 1993, 21: 2265-6 ; Griffiths et al., EMBO J. 1994, 13: 3245-60 ; Vaughan et al., Nature Biotechnology 1996, 14: 309-14 ; and Japanese Patent Kohyo Publication No.
  • variable regions of human antibodies can be expressed on the surface of phages as single chain antibodies (scFvs) using phage display methods, and phages that bind to antigens can be selected. Genetic analysis of the selected phages can determine the DNA sequences encoding the variable regions of human antibodies that bind to the antigens.
  • suitable expression vectors can be produced based on these sequences to obtain human antibodies. These methods are already well known, and one can refer to WO92/01047 , WO92/20791 , WO93/06213 , WO93/11236 , WO93/19172 , WO95/01438 , and WO95/15388 .
  • known techniques may be used, involving the use of desired antigens or cells expressing the desired antigens as sensitizing antigens, using these to perform immunizations according to conventional immunization methods, fusing the immune cells thus obtained with known parent cells by ordinary cell fusion methods, screening monoclonal antibody producing cells (hybridomas) by ordinary screening methods, synthesizing cDNAs of antibody variable regions (V regions) from mRNAs of the obtained hybridomas using reverse transcriptase, and linking them with DNAs encoding the desired antibody constant regions (C regions).
  • V regions antibody variable regions
  • C regions desired antibody constant regions
  • sensitizing antigens for obtaining the above-mentioned antibody genes encoding the H chains and L chains include both complete antigens with immunogenicity and incomplete antigens composed of haptens and such that do not show antigenicity.
  • full length proteins and partial peptides of proteins of interest can be used.
  • substances composed of polysaccharides, nucleic acids, lipids, and such may become antigens.
  • Antigens can be prepared by methods known to those skilled in the art, and they can be prepared, for example, by the following methods using baculoviruses (for example, WO98/46777 ).
  • Hybridomas can be produced, for example, the following methods of Milstein et al. (a Kohler and C. Milstein, Methods Enzymol. 1981, 73: 3-46 ), and such.
  • an antigen When the immunogenicity of an antigen is low, it can be linked to a macromolecule that has immunogenicity, such as albumin, and then used for immunization.
  • antigens with other molecules if necessary, they can be converted into soluble antigens.
  • transmembrane molecules such as receptors are used as antigens, portions of the extracellular regions of the receptors can be used as a fragment, or cells expressing transmembrane molecules on their cell surface may be used as immunogens.
  • Antibody-producing cells can be obtained by immunizing animals using suitable sensitizing antigens described above. Alternatively, antibody-producing cells can be prepared by in vitro immunization of lymphocytes that can produce antibodies. Various mammals can be used as the animals for immunization, where rodents, lagomorphas and primates are generally used. Examples of such animals include mice, rats, and hamsters for rodents, rabbits for lagomorphas, and monkeys including the cynomolgus monkey, rhesus monkey, hamadryas, and chimpanzees for primates.
  • transgenic animals carrying human antibody gene repertoires are also known, and human antibodies can be obtained by using these animals (see WO96/34096 ; Mendez et al., Nat. Genet. 1997, 15: 146-56 ).
  • desired human antibodies having binding activity against antigens can be obtained by in vitro sensitization of human lymphocytes with desired antigens or cells expressing the desired antigens, and then fusing the sensitized lymphocytes with human myeloma cells such as U266 (see Japanese Patent Application Kokoku Publication No. ( JP-B) H1-59878 (examined, approved Japanese patent application published for opposition)).
  • desired human antibodies can be obtained by immunizing transgenic animals carrying a complete repertoire of human antibody genes, with desired antigens (see WO93/12227 , WO92/03918 , WO94/02602 , WO96/34096 , and WO96/33735 ).
  • Animal immunization can be carried out by appropriately diluting and suspending a sensitizing antigen in Phosphate-Buffered Saline (PBS), physiological saline, or such, and forming an emulsion by mixing an adjuvant if necessary, followed by an intraperitoneal or subcutaneous injection into animals. After that, the sensitizing antigen mixed with Freund's incomplete adjuvant is preferably administered several times every four to 21 days. Antibody production can be confirmed by measuring the target antibody titer in animal sera using conventional methods.
  • PBS Phosphate-Buffered Saline
  • physiological saline physiological saline
  • Antibody production can be confirmed by measuring the target antibody titer in animal sera using conventional methods.
  • Antibody-producing cells obtained from lymphocytes or animals immunized with a desired antigen can be fused with myeloma cells to generate hybridomas using conventional fusing agents (for example, polyethylene glycol) (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, 1986, 59-103).
  • fusing agents for example, polyethylene glycol
  • hybridoma cells can be cultured and grown, and the binding specificity of the antibody produced from these hybridomas can be measured using known analysis methods, such as immunoprecipitation, radioimmunoassay
  • hybridomas that produce antibodies of interest whose specificity, affinity, or activity has been determined can be subcloned by methods such as limiting dilution.
  • genes encoding the selected antibodies can be cloned from hybridomas or antibody-producing cells (sensitized lymphocytes, and such) using probes that may specifically bind to the antibodies (for example, oligonucleotides complementary to sequences encoding the antibody constant regions). Cloning from mRNA using RT-PCR is also possible.
  • Immunoglobulins are classified into five different classes, IgA, IgD, IgE, IgG and IgM. These classes are further divided into several subclasses (isotypes) (for example, IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2; and such).
  • H chains and L chains used in the present invention to produce antibodies are not particularly limited and may derive from antibodies belonging to any of these classes or subclasses; however, IgG is particularly preferred.
  • H-chain-encoding genes and L-chain-encoding genes using genetic engineering techniques.
  • Genetically modified antibodies such as chimeric antibodies, humanized antibodies that have been artificially modified for the purpose of decreasing heterologous antigenicity and such against humans, can be appropriately produced if necessary for antibodies such as mouse antibodies, rat antibodies, rabbit antibodies, hamster antibodies, sheep antibodies, and camel antibodies.
  • Chimeric antibodies are antibodies composed of a nonhuman mammal antibody H chain and L chain variable regions, such as mouse antibody, and the H chain and L chain constant regions of human antibody.
  • a humanized antibody which is also called a reshaped human antibody, can be synthesized by PCR from a number of oligonucleotides produced so that they have overlapping portions at the ends of DNA sequences designed to link the complementary determining regions (CDRs) of an antibody of a nonhuman mammal such as a mouse.
  • the obtained DNA can be ligated to a DNA encoding a human antibody constant region.
  • the ligated DNA can be incorporated into an expression vector, and the vector can be introduced into a host to produce the antibody (see EP239400 and WO96/02576 ).
  • Human antibody FRs that are ligated via the CDR are selected when the CDR forms a favorable antigen-binding site. If necessary, amino acids in the framework region of an antibody variable region may be substituted such that the CDR of the reshaped human antibody forms an appropriate antigen-binding site ( K. Sato et al., Cancer Res. 1993, 53: 851-856 ).
  • antibodies may be modified to improve their biological properties, for example, antigenic affinity.
  • modifications can be carried out using methods such as site-directed mutagenesis (see for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82: 488 ), PCR mutagenesis, and cassette mutagenesis.
  • mutant antibodies whose biological properties have been improved show amino acid sequence homology and/or similarity of 70% or higher, more preferably 80% or higher, and even more preferably 90% or higher (for example, 95% or higher, 97%, 98%, 99%, etc.), when compared to the amino acid sequence of the original antibody variable region.
  • sequence homology and/or similarity is defined as the ratio of amino acid residues that are homologous (same residue) or similar (amino acid residues classified into the same group based on the general properties of amino acid side chains) to the original antibody residues, after the sequence homology value has been maximized by sequence alignment and gap introduction, if necessary.
  • amino acid residues are classified into groups based on the characteristics of their side chains: (1) hydrophobic: alanine, isoleucine, valine, methionine, and leucine; (2) neutral hydrophilic: asparagine, glutamine, cysteine, threonine, and serine; (3) acidic: aspartic acid, and glutamic acid; (4) basic: arginine, histidine, and lysine; (5) residues that affect the orientation of the chain: glycine, and proline; and (5) aromatic: tyrosine, tryptophan, and phenylalanine.
  • CDRs complementary determining regions
  • hypervariable regions present in the H chain and L chain variable regions interact to form the antigen binding site(s) of an antibody.
  • CDRs complementary determining regions
  • variable regions are known to have the ability to recognize and bind to the antigen, although the affinity will be lower than when all binding sites are included. Therefore, antibody genes of the present invention encoding the H chain and L chain only have to encode fragment portions having each of the antigen binding sites of H chain and L chain, and polypeptides encoded by these genes only have to maintain affinity with the desired antigens.
  • desired bispecific antibodies that actually have activities can be obtained efficiently by the methods of the present invention.
  • Heavy chain variable regions are generally composed of three CDR regions and four FR regions, as described above.
  • amino acid residues subjected to "modification” can be appropriately selected, for example, from amino acid residues in the CDR regions or FR regions.
  • modification of amino acid residues in the CDR regions can decrease affinity towards antigens. Therefore, in the present invention, amino acid residues subjected to "modification” are not particularly limited, but are preferably appropriately selected from amino acid residues in the FR regions.
  • variable region FRs for antibodies in organisms such as human or mouse
  • sequences that can be used as variable region FRs for antibodies in organisms such as human or mouse can be appropriately obtained by those skilled in the art using public databases. More specifically, amino acid sequence information of the FR regions can be obtained by means described later in the Examples.
  • a database was constructed by obtaining amino acid sequence data of human antibodies from the publicly disclosed in Kabat Database (ftp://ftp.ebi.ac.uk/pub/databases/kabat/) and IMGT Database (http://imgt.cines.fr/), and homology search was performed on the database for the mouse A69 H chain variable region (amino acid sequence: SEQ ID NO: 19), mouse B26 H chain variable region (amino acid sequence: SEQ ID NO: 20), and mouse BBA L chain variable region (amino acid sequence: SEQ ID NO: 21).
  • the results confirmed that they have high homologies to the human antibody sequences below, and it was thus decided that they could be used as framework region (hereinafter referred to as FR) for humanized antibodies.
  • the complementary determining region (hereinafter referred to as CDR) of each of the mouse antibodies was grafted into the FR of human antibodies of (1)-(3), and humanized antibodies were thus prepared.
  • homology search web site publicly disclosed by NCBI (http://www.ncbi.nlm.nih.gov/BLAST/) was used to search for secretory signal sequences of human antibodies that are highly homologous to human antibodies of (4)-(6).
  • the following secretory signal sequences obtained by the search were used.
  • nucleotide sequence encoding the amino acid sequence covering from the secretory signal sequence to the antibody variable region twelve synthetic oligo-DNAs of about 50 bases were prepared, such that about 20 bases at the 3' end hybridize with each other.
  • the synthetic oligo-DNAs were designed such that they encode a human sequence at the 5' side and a mouse sequence at the 3' side, or such that all the nucleotides encode a human sequence.
  • a primer that anneals to the 5'-end of an antibody variable region gene and has the Xhol cleavage sequence and a primer that encodes the 5'-end sequence of the intron sequence, anneals to the 3'-end of an antibody variable region gene, and has the SfiI cleavage sequence were prepared.
  • the fragments were cloned using the pGEM-T Easy Vector System (Promega) according to the method described in the attached instruction manual.
  • the nucleotide sequence of each DNA fragment was determined using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) and ABI PRISM 3730xL DNA Sequencer or ABI PRISM 3700 DNA Sequencer (Applied Biosystems) according to the method described in the attached instruction manual.
  • the H-chain variable region fragment-inserted plasmid was digested with XhoI and SfiI, and the L-chain variable region fragment-inserted plasmid was digested with EcoRI, after they were confirmed to have the correct humanized antibody variable region gene sequence. Then, the reaction solutions were subjected to 1% agarose gel electrophoresis. DNA fragments having the desired size (about 400 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the method described in the attached instruction manual, and eluted with 30 ⁇ L of sterilized water. Thereafter, vectors for expression in animal cells were prepared as follows.
  • an IgG4 that has amino acid substitution in its CH3 portion was used by referring to the knobs-into-holes technique for IgG1 ( Merchant AM et al., Nature Biotechnology, 1998, Vol. 16, p. 677-681 ). Furthermore, to promote H-chain dimer formation, amino acid substitution (-ppcpScp- ⁇ -ppcpPcp-) was also introduced into the hinge.
  • Humanized A69 H chain expression vector was prepared by inserting the humanized A69 H chain variable region antibody gene fragment into an expression vector prepared by inserting an Y349C and T366W-substituted constant region gene into pCAGGS comprising a chicken ⁇ -actin promoter ( Niwa et al., Gene, 1991, 108: 193-199 ).
  • Humanized B26 H chain expression vector was prepared by inserting the humanized B26 H chain variable region antibody gene fragment into an expression vector prepared by inserting an E356C, T366S, L368A, and Y407V-substituted constant region gene to pCAGGS.
  • the plasmid (pCAG-gxDNA) was prepared by inserting a wild-type antibody L chain constant region into pCAGGS, and was digested with EcoRI to prepare an expression vector into which the humanized BBA L chain variable region antibody gene fragment was inserted. Ligation reaction was performed using the Rapid DNA Ligation Kit (Roche Diagnostics), and the E. coli strain DH5 ⁇ (TOYOBO) was transformed.
  • Humanized bispecific antibodies were expressed using the following method. Human fetal renal carcinoma cell-derived humanized bispecific antibodies were expressed using the method described in Example 1-2, or using the following method. Human fetal renal carcinoma cell-derived HEK293H strain (Invitrogen) was suspended in a DMEM medium (Invitrogen) containing 10% Fetal Bovine Serum (Invitrogen), seeded at a cell density of 5-6 x 10 5 cells/mL (10 mL per dish) in dishes used for adhesive cells (10-cm diameter, CORNING), and cultured for one day and night in a CO 2 incubator (37°C, 5% CO 2 ).
  • DMEM medium Invitrogen
  • Fetal Bovine Serum Fetal Bovine Serum
  • CHO-S-SFM-II Invitrogen
  • Fetal Bovine Serum Fetal Bovine Serum
  • the plasmid DNA mixture solution prepared in 1-2 was mixed with 20.7 ⁇ L of 1 ⁇ g/mL Polyethylenimine (Polysciences Inc.) and 690 ⁇ L of CHO-S-SFMII medium, left to stand at room temperature for ten minutes, and then added to the cells in each dish.
  • the cells were then incubated in a CO 2 incubator (37°C, 5% CO 2 ) for four to five hours.
  • CHO-S-SFM-II Invitrogen
  • Fetal Bovine Serum Invitrogen
  • the culture supernatant was collected, then cells were removed by centrifugation (at approximately 2000 g for five minutes at room temperature), and the solution was sterilized by passing it through a 0.22 ⁇ m filter MILLEX ® -GV (Millipore). The sample was stored at 4°C until use.
  • rProtein A Sepharose TM Fast Flow 100 ⁇ L of rProtein A Sepharose TM Fast Flow (Amersham Biosciences) was added to the culture supernatant obtained by the method described in Example 1-2, and the solution was mixed by rotation at 4°C for four hours. The solution was transferred to an Ultrafree ® -MC 0.22- ⁇ m filter cup (Millipore). After three washes with 500 ⁇ L of TBS containing 0.01% Tween ® 20, the rProtein A Sepharose TM resin was suspended in 100 ⁇ L of 50 mM aqueous sodium acetate solution containing 0.01% Tween ® 20 at pH 3.3, and left to stand for two minutes, and then, the antibody was eluted. The eluate was immediately neutralized by adding 6.7 ⁇ L of 1.5 M Tris-HCl, pH 7.8.
  • Goat anti-human IgG (Biosource International) was adjusted to 1 ⁇ g/mL with a coating buffer, and immobilized to a Nunc-Immuno plate (Nunc). After blocking with a diluent buffer (D.B.), a sample of the culture supernatant suitably diluted with D.B. was added. Furthermore, eleven three-fold serial dilutions of human IgG4 (humanized anti-TF antibody, see WO 99/51743 ) starting from 2000 ng/mL were made with D.B., and added as a standard for antibody concentration calculation. After three washes, goat anti-human IgG, alkaline phosphatase (Biosource International) was added for reaction.
  • D.B. diluent buffer
  • human IgG4 humanized anti-TF antibody, see WO 99/51743
  • measurements were performed with Biacore 1000 (BIACORE) using Protein A-immobilized Sensor Chip CM5 (BIACORE). More specifically, according to the manufacturer's protocol, an activated sensor chip was reacted with Protein A (SIGMA) solution diluted to 50 ⁇ g/mL with 10 mM aqueous sodium acetate solution (pH 4.0, BIACORE) at 5 ⁇ L/minute for 30 minutes, and then a blocking procedure was carried out to produce a Protein A-immobilized sensor chip. This sensor chip was used to measure the concentrations of the culture supernatant and the purified products on Biacore 1000 (BIACORE). HBS-EP Buffer (BIACORE) was used for the immobilization of the sensor chip and for the concentration measurements.
  • SIGMA Protein A
  • HBS-EP Buffer BIACORE
  • APTT activated partial thromboplastin time
  • the Factor VIII-like activity (%) of a bispecific antibody was calculated from the coagulation time measured when the bispecific antibody was added.
  • the human antibody FR of humanized bispecific antibodies that displayed decreased blood coagulation ability in the above-mentioned blood coagulation activity assay were subjected to amino acid modification in order to increase the activity. More specifically, the QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used to introduce mutations into the humanized antibody variable region according to the method described in the attached instruction manual. The H-chain variable region fragment-inserted plasmid digested with XhoI and SfiI, and the L-chain variable region fragment-inserted plasmid was digested with EcoRI, , after they were confirmed to have the desired humanized antibody variable region gene sequence. Then, the reaction solutions were subjected to 1% agarose gel electrophoresis.
  • DNA fragments having the desired size (about 400 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the method described in the attached instruction manual, and eluted with 30 ⁇ L of sterilized water. Then, plasmids for expression in animal cells were prepared according to the method described in Example 1-2. Humanized bispecific antibodies were prepared according to the method described in Examples 1-3, 1-4, and 1-5, and blood coagulation activity was evaluated according to the method described in Example 1-6.
  • a humanized bispecific antibody (humanized A69 (hA69a)/humanized B26 (hB26-F123e4)/humanized BBA (hAL-F123j4)) having the same level of activity as the chimeric bispecific antibody (A69/B26/BBA) was obtained ( Fig. 1 ).
  • the antibody variable region sequences are shown in the following SEQ ID NOs.
  • a bispecific antibody In preparation of a bispecific antibody, when two types of H chains and one type of L chain are used for expression, the following three types of antibodies are expressed: a homodimer of the humanized A69 H chain and humanized BBA L chain, a homodimer of the humanized B26 H chain and humanized BBA L chain, and a heterodimer of the humanized A69 H chain, humanized B26 H chain, and humanized BBA L chain.
  • the objective is to purify only the bispecific antibody by separating these three types of antibodies, and thus amino acid modifications were carried out to decrease the isoelectric point of the humanized A69 H chain variable region and increase the isoelectric point of the humanized B26 H chain variable region.
  • antibody Fv region models were prepared for the humanized A69 antibody and humanized B26 antibody by homology modeling using the MOE software (Chemical Computing Group Inc.), and the amino acid resides exposed on the surface of the variable regions of the humanized A69 antibody and humanized B26 antibody were confirmed.
  • the models are shown in Fig. 2 .
  • the surface-exposed amino acids in the FR sequence outside CDR, H10, H12, H23, H39, H43, and H105 are thought to be candidates that can alter the isoelectric point without decreasing the activity.
  • DNA fragments having the desired size (about 400 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the method described in the attached instruction manual, and eluted with 30 ⁇ L of sterilized water.
  • H-chain expression vectors were prepared by inserting the prepared DNA fragments into an expression plasmid carrying a wild-type constant region and an expression plasmid in which the constant region amino acids have been replaced using the knobs-into-holes technique.
  • humanized bispecific antibodies were prepared by the method described in Examples 1-3, 1-4, and 1-5. Sequences of the modified humanized antibody variable regions are shown in the SEQ ID NOs in Table 1 shown below.
  • modified antibodies were prepared and analyzed by isoelectric focusing.
  • the humanized BBA L-chain (hAL-F123j4) expression vector was simultaneously expressed together with the H-chain expression vector of unmodified hA69a, or hA69-p18, hA69-p8, hA69-p17, or hA69-p16 modified from the humanized A69 H chain.
  • Five types of antibodies composed of hA69a, hA69-p18, hA69-p8, hA69-p17, or hA69-p16 homodimers were prepared.
  • the humanized BBA L-chain expression vector was simultaneously expressed together with the H-chain expression vector of unmodified hB26-F123e4, or hB26-p19 or hB26-p15 modified from the humanized B26 H chain.
  • Three types of antibodies composed of hB26-F123e4, hB26-p19, or hB26-p15 homodimers were prepared. Isoelectric focusing was performed as follows. PhastGel Dry IEF gel (Amersham Biosciences) was swollen for about 30 minutes in the swelling solution described below using the Phastsystem Cassette (Amersham Biosciences).
  • Electrophoresis was performed using the swollen gel by PhastSystem (Amersham Biosciences) according to the following program. The samples were applied to the gel in Step 2. ApI calibration kit (Amersham Biosciences) was used as the pI marker. Step 1: 2000 V 2.5 mA 3.5 W 15°C 75 Vh Step 2: 200 V 2.5 mA 3.5 W 15°C 15 Vh Step 3: 2000 V 2.5 mA 3.5 W 15°C 410 Vh
  • the gel was fixed with 20% TCA, and then silver stained using a silver staining kit, protein (Amersham Biosciences) according to the protocol attached to the kit. After staining, the isoelectric points of the samples were calculated from the known isoelectric points of the pI marker.
  • the results of analysis of the unmodified and modified humanized A69 antibody homodimers and the humanized B26 antibody homodimer are shown in Fig. 3 .
  • Band shifts were observed in the isoelectric focusing due to modification of the surface charge.
  • the isoelectric points of the respective antibodies estimated in reference to the pI marker were approximately 8.4 for modified hA69-p18, approximately 8.2 for modified hA69-p17, approximately 8.2 for modified hA69-p8, and approximately 8.1 for modified hA69-p16, in contrast to approximately 8.8 for the unmodified hA69a homodimer. That is, the modification was able to provide a maximum isoelectric point difference of approximately 0.7.
  • the isoelectric points were approximately 9.3 for modified hB26-p19 and approximately 9.4 for modified hB26-p15, in contrast to approximately 9.1 for unmodified hB26-F123e4. That is, the modification was able to provide a maximum isoelectric point difference of approximately 0.3. It was shown that the isoelectric point can be altered by modifying the charges on the surface amino acids in the variable region selected for this examination: H12, H23, H39, H43, and H105.
  • Cation exchange chromagographic analysis was performed by the following method using the modified antibodies produced in Example 4 to evaluate the effect of the modification on the separation of the two antibodies.
  • the conditions for the cation exchange chromatographic analysis were as follows. The retention time was calculated for the humanized A69 antibody homodimer and the humanized B26 antibody homodimer.
  • Peak shifts were observed when comparing the unmodified humanized B26 antibody with those that have been modified to have higher isoelectric points for the variable region, and the retention time was increased to approximately 28.4 minutes and approximately 29.4 minutes, as the number of modifications increased.
  • the retention time can be altered by modifying the charges on the surface amino acids in the variable region selected for this examination, H12, H23, H39, H43, and H105, and thereby modifying the surface charges of the two types of antibodies.
  • Example 4 According to the isoelectric point measurements in Example 4, despite a pI difference of 0.3 between the unmodified hA69a homodimer and the unmodified hB26-F123e4 homodimer, the retention time for both of the homodimers was around 25 minutes, and thus they could not be separated ( Fig. 9 ). However, the pI difference between the unmodified hA69a homodimer and hB26-p19 was 0.5, and thus they were separated by a retention time difference of approximately 2.6 minutes. Also, the pI difference between hA69-p18 and the hB26 homodimer was 0.7, and thus they were separated by a retention time difference of approximately 3.4 minutes.
  • APTT activated partial thromboplastin time
  • Coagulation reaction was initiated by adding 50 ⁇ L of 20 mM CaCl 2 (Dade Behring) to the mixture. The time period until coagulation was measured with KC10A (Amelung) linked to CR-A (Amelung).
  • the Factor VIII-like activity (%) of a bispecific antibody was calculated from the coagulation time measured when the bispecific antibody was added.
  • H97 was confirmed to be a surface-exposed amino acid.
  • the humanized A69 H chain hA69-N97R has a sequence in which asparagine at position 97 in CDR3 has been replaced with arginine.
  • Modified antibodies were prepared by producing an expression vector carrying hA69-N97R according to the method of Example 1-2, and expressing it together with the humanized BBA L chain hAL-F123j4. To evaluate the alteration of surface charge of this antibody, isoelectric focusing was performed according to the method of Example 4. As indicated in Fig.
  • Factor IXa the activity of binding to the antigen, Factor IXa was assayed by the following method.
  • Factor IXa ⁇ Enzyme Research Laboratories
  • coating buffer 100 mM sodium bicarbonate, pH 9.6, 0.02% sodium azide
  • the plate was blocked with diluent buffer (50 mM Tris-HCl, pH 8.1,1% bovine serum albumin, 1 mM MgCl 2 , 0.15 M NaCl, 0.05% Tween ® 20, 0.02% sodium azide) at room temperature for two hours. After removal of the buffer, a purified antibody diluted in the diluent buffer was added to the plate at 100 ⁇ L/well and incubated at room temperature for one hour.
  • diluent buffer 50 mM Tris-HCl, pH 8.1,1% bovine serum albumin, 1 mM MgCl 2 , 0.15 M NaCl, 0.05% Tween ® 20, 0.02% sodium azide
  • the plate was washed three times, then alkaline phosphatase-labeled goat anti-mouse IgG (BIOSOURCE) diluted at 1/4000 with the diluent buffer was added at 100 ⁇ L/well. This was then incubated at room temperature for one hour. The plate was washed five times, then a chromogenic substrate (Sigma) was added at 100 ⁇ L/well. This was then incubated at room temperature for 30 minutes. The absorbance at 405 nm (control: 655 nm) was measured using the Model 3550 Microplate Reader (Bio-Rad Laboratories). As a result, as shown in Fig.
  • the antibody in which the CDR had been modified to alter the surface charge showed a binding activity equivalent to that of the antibody before modification.
  • the sites of modification may not only be in the FR indicated in Example 5, but also in the CDR.
  • An unmodified humanized bispecific antibody was prepared using the unmodified antibodies (humanized A69 H chain hA69a and humanized B26 H chain hB26-F123e4) shown in Table 1, as well as the humanized BBAL chain hAL-F123j4 (SEQ ID NO: 5).
  • a humanized bispecific PF antibody was prepared using the modified antibodies (the modified form of the humanized A69 H chain hA69-PFL and the modified form of the humanized B26 H chain hB26-PF) shown in Table 1, as well as the humanized BBA L chain hAL-s8 (SEQ ID NO: 17).
  • H-chain expression vectors were prepared using an expression vector carrying the wild-type constant region, and the antibodies were prepared by the method described in Examples 1-3, 1-4, and 1-5.
  • cation exchange chromatographic analysis was carried out according to the method described in Example 5.
  • Figs. 9 and 10 The results of analysis of the unmodified humanized bispecific antibody and humanized bispecific PF antibody are shown in Figs. 9 and 10 .
  • the results showed that the two types of homodimers and the bispecific antibody failed to separate, and were eluted as a single peak.
  • the humanized bispecific PF antibody each of the two types of homodimers and the desired bispecific antibody were separated, and were eluted as three peaks in the following order: hA69-PF homodimer, humanized bispecific PF antibody, and hB26-PF homodimer.
  • the two types of homodimers and the humanized bispecific PF antibody were purified. These fractions were concentrated using Amicon Ultra, MWCO 10000 (Millipore), then dialyzed overnight against 20 mM sodium acetate, 150 mM NaCl, pH 6.0 while cooling. Then, the concentrations were measured.
  • the isoelectric point difference between the humanized A69-PF antibody homodimer and the humanized bispecific PF antibody was approximately 0.7, while the isoelectric point difference between the humanized B26-PF antibody homodimer and the humanized bispecific PF antibody was approximately 0.6.
  • the coagulation activity of the bispecific PF antibody purified according to the method described in Example 6 was evaluated.
  • the coagulation activity was compared with those of the following three types of antibodies expressed using an IgG4 constant region with the knobs-into-holes technique: the aforementioned chimeric bispecific antibody; the bispecific antibody composed of hA69a (SEQ ID NO: 2), hB26-F123e4 (SEQ ID NO: 4), and hAL-F123j4 (SEQ ID NO: 6) whose variable regions were not modified; and the bispecific antibody having the same variable regions as those of the purified bispecific PF antibody.
  • the results of the evaluation are shown in Fig. 12 .
  • the coagulation activity of the bispecific PF antibody carrying an IgG4 constant region prepared based on the knobs-into-holes technique was equivalent to that of the bispecific PF antibody carrying a wild-type constant region purified by cation exchange chromatography.
  • modifications at H10, H12, H23, H39, H43, and H105 in the variable region enable purification of bispecific antibodies to a high purity without affecting their activities.
  • antibody-expressing cell lines were established as follows.
  • the H-chain constant region was amplified by PCR using the wild-type H-chain constant region gene of human IgG4 as a template, as well as a 5'-end primer designed such that the nucleotide sequence encoding the two amino acids (Ala-Ser) at the N terminus of the H-chain constant region will be the NheI recognition sequence (GCTAGC), and a primer designed to anneal to the 3'-end and carry the NotI recognizing site, and was linked to a vector prepared by digesting the pBluescriptKS+ vector (TOYOBO) with NheI and NotI (both from Takara), to produce pBCH4 comprising the IgG4 constant region gene.
  • a 5'-end primer designed such that the nucleotide sequence encoding the two amino acids (Ala-Ser) at the N terminus of the H-chain constant region will be the NheI recognition sequence (GCTAGC), and a primer designed to anneal to the 3'-end and carry the NotI recognizing
  • PCR was performed using a primer that is complementary to the 5'-end nucleotide sequence of the H-chain variable region of the humanized A69 H chain antibody (hA69-KQ) and humanized B26 H chain antibody (hB26-PF) shown in Table 1, and which has a Kozak sequence (CCACC) and the EcoRI recognition sequence, and a primer to the 3'-end nucleotide sequence and has the NheI recognition sequence.
  • the obtained PCR products were digested with EcoRI and NheI (both from Takara), and were inserted into pBCH4 similarly digested with EcoRI and NheI, to link the variable region and the constant region.
  • the prepared humanized A69 H chain antibody vector was digested with EcoRI and NheI (both from Takara), and was cloned into the pCXND3 expression vector for animal cells similarly digested with EcoRI and NotI.
  • the course of construction of the present vector pCXND3 will be described below.
  • To separate the antibody H chain gene and the vector in DHFR- ⁇ E-rVH-PM1-f (see WO92/19759 ), it was digested at the EcoRI and SmaI restriction sites to recover only the vector part. Subsequently, the EcoRI-NotI-BamHI adaptor (Takara) was cloned into this vector. The resulting vector was named pCHOI.
  • the region of pCHOI for expressing the DHFR gene was cloned into the HindIII restriction site of pCXN ( Niwa et al., Gene 1991; 108: 193-200 ).
  • the resulting vector was named pCXND3.
  • the prepared humanized B26 H chain antibody vector was digested with EcoRI and NotI (both from Takara), and was cloned in the pCXZD1 expression vector for animal cells similarly digested with EcoRI and NotI.
  • the pCXZD1 vector is an expression vector in which the neomycin resistance gene of the pCXND3 vector has been replaced with a Zeocin resistance gene.
  • PCR was performed using a synthetic oligonucleotide that is complementary to the 5'-end nucleotide sequence of the L chain variable region of the humanized BBA L chain antibody (hAL-AQ, SEQ ID NO: 18) and which has a Kozak sequence, and a synthetic oligonucleotide that is complementary to the 3'-end nucleotide sequence and has the BsiWI site.
  • the obtained PCR product was cloned in the pBCL vector, in which the human kappa chain constant region was inserted into the pBluescript KS+ vector.
  • the human L chain variable region and constant region were linked together via the BsiWI site.
  • the produced L chain gene fragment was cloned into the expression vector pUCAG.
  • the pUCAG vector was prepared by digesting pCXN ( Niwa et al., Gene 1991; 108: 193-200 ) with the restriction enzyme BamHI to obtain a 2.6-kbp fragment, and cloning the fragment into the BamHI restriction site of the pUC19 vector (TOYOBO).
  • the vector produced by cloning the L chain into pUCAG was digested with the restriction enzyme BamHI, and this was cloned into the expression vector pHygDHFR-4b containing a hygromycin resistance gene.
  • the three types of expression vectors thus produced were linearized with restriction enzymes, and then they were transfected into CHO-DG44 cells to establish antibody-expressing cell lines.
  • a ten-fold diluted solution was prepared using the same culture medium, and added at 100 ⁇ L/well to a 96-well culture plate. After culturing in a CO 2 incubator (5% CO 2 ) for one day and night, Geneticin (Invitrogen), Zeocin (Invitrogen), and Hygromycin B (Invitrogen) were added at 0.5 mg/mL, 0.6 mg/mL, and 0.4 mg/mL, respectively, and culture was continued for two weeks. Colonies of transfected cells showing drug resistance were sequentially cultured and expanded. Large scale culturing was carried out using the established high expression cell lines, and the culture supernatant was obtained.
  • Bispecific antibodies were purified from the culture supernatant obtained in Example 8 by the following method.
  • Solvent A 20 mmol/L sodium acetate buffer, pH 6.0
  • Solvent B 20 mmol/L sodium acetate buffer, 1 mol/L NaCl, pH 6.0
  • Flow Rate 10 mL/min (113 cm/h), or 5.3 mL/min (60 cm/h) only at the time of elution
  • Gradient 0 ⁇ 15%
  • B Step wise 3 Column Volume (CV) flushed 15 ⁇ 22% B gradient 2.5 CV 22 ⁇ 30% B gradient 6 CV 30 ⁇ 100% B Step wise 3 CV flushed
  • bispecific antibodies can be also separated and purified using a standard preparative column.
  • the coagulation activity of the humanized bispecific antibody prepared in Example 9 was evaluated according to the method described in Example 6. The results of the evaluation are shown in Fig. 14 .
  • the humanized bispecific antibody purified in Example 9 had a coagulation activity equivalent to that of the humanized bispecific PF antibody prepared in Example 8. Thus, it was shown that even if amino acid sequences of the variable regions are slightly different in hA69-PFL and hA69-KQ, or even if the antibodies are purified using a standard preparative column, the antibody activities were not affected.
  • the humanized bispecific antibody of interest and the two types of homodimeric antibodies can be separated and purified without modifying the structure or function (activity) of the antibody, by altering the surface charge through modification of the H-chain variable region when preparing the bispecific antibody. Since it was shown that bispecific antibodies can be separated and purified on a standard preparative column using the present method, this will be useful as a method for producing pharmaceuticals comprising a bispecific antibody.
  • reaction solution (1 ⁇ L each of 20 ⁇ M K62 primer (5' cac cgt etc etc age etc cac caa 3', SEQ ID NO: 22) and K63 primer (5' gtg gca etc att tac ccg gag aca 3', SEQ ID NO: 23), 5 ⁇ L of MTC Multiple Tissue cDNA Panels (peripheral leukocytes) (Clontech), 4 ⁇ L of 5 ⁇ Prime STAR Buffer, 4 ⁇ L of 2.5 mM dNTPs, and 1 ⁇ L of PrimeSTAR HS DNA Polymerase (the above from Takara)) was prepared, and this was subjected to PCR.
  • reaction solution 1 ⁇ L each of 20 ⁇ M K62 primer (5' cac cgt etc etc age etc cac caa 3', SEQ ID NO: 22) and K63 primer (5' gtg gca etc att tac ccg gag aca 3', SEQ ID NO: 23
  • PCR was performed using a thermal cycler. GeneAmp PCR system 9700 (Perkin Elmer), by heating at 98°C for two minutes, followed by 30 cycles of reacting at 98°C for ten seconds, 60°C for five seconds, and 72°C for two minutes per cycle, and finally heating at 72°C for ten minutes. After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis. Amplified fragments having the size of interest (approximately 1000 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the method described in the attached instruction manual, and eluted with 50 ⁇ L of sterile water.
  • QIAquick Gel Extraction Kit QIAquick Gel Extraction Kit
  • r-Taq treatment was performed to add A (Adenosine) to the ends of the amplified fragments.
  • A Addenosine
  • the obtained amplified fragments were incubated in 10 ⁇ L of rTaq reaction solution (1 ⁇ L of 10 ⁇ rTaq reaction solution, 1 ⁇ L of 2.5 mM dNTPs, 1 ⁇ L of rTaq, and 7 ⁇ L of the above-mentioned amplified fragments) at 72°C for 30 minutes.
  • the r-Taq-treated fragments were cloned into the pCR2.1-TOPO vector (Invitrogen), and the nucleotide sequences were determined.
  • the nucleotide sequence of each DNA fragment was determined by a DNA sequencer ABI PRISM 3730xL Genetic Analyzer (Applied Biosystems) using the BigDye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems) according to the method described in the attached instruction manual.
  • the determined nucleotide sequences were compared to the sequence of Accession No. BX640623. If nucleotides in a determined sequence encode an amino acid sequence different from the corresponding sequence of BX640623, such nucleotides were considered to be mutations inserted during PCR amplification. In such cases, amino acid substitutions were performed using the Quick Change Site-Directed Mutagenesis Kit (Stratagene) so that the amino acid sequence will be the same as that of BX640623. The Quick Change Site-Directed Mutagenesis Kit (Stratagene) was used according to the method described in the attached instruction manual.
  • a mutation was introduced such that the first two amino acids (Ala-Ser) of the human IgG2 H chain constant region were encoded by the restriction enzyme NheI recognition sequence (GCTAGC).
  • the nucleotide sequence and amino acid sequence of the human IgG2 H-chain constant region used in this examination are shown in SEQ ID NOs: 24 and 25, respectively.
  • Antibody expression vectors in which the H-chain variable region of the humanized PM-1 antibody is linked to one of the H chain constant regions of human IgG 1, human IgG2, and human IgG4, were prepared as follows.
  • PCR was performed using a synthetic oligonucleotide that has a Kozak sequence and is complementary to the 5'-end nucleotide sequence of the H-chain variable region of the humanized anti-human interleukin 6 receptor antibody (humanized PM-1 antibody) described in a Non-Patent Document ( Sato K. et al., Cancer Research 1993, 53:851-856 ), and a synthetic oligonucleotide that has the NheI recognition sequence and is complementary to the 3'-end nucleotide sequence.
  • the obtained PCR product was cloned into the pB-CH vector, in which the human IgG1 H chain constant region (see Sato, K.
  • H-chain variable region gene of the humanized PM-1 antibody was linked to the human IgG4 constant region gene (see WO 99/51743 ) or the human IgG2 H chain gene prepared in Example 11-1 via the 5'-end NheI site, and then inserted into the pCAGGS vector.
  • Each H-chain expression vector expresses the H chain by linking the H-chain variable region of the humanized PM-1 antibody to the humanized H chain constant region via the Nhel sequence.
  • PCR was performed using a synthetic oligonucleotide that has a Kozak sequence and is complementary to the 5'-end nucleotide sequence of the L-chain variable region of the humanized PM-1 antibody, and a synthetic oligonucleotide that has the restriction enzyme BsiWI recognition sequence and is complementary to the 3'-end nucleotide sequence.
  • the obtained PCR product was cloned into the pB-CL vector, in which the human kappa chain constant region was inserted into the pBluescript KS+ vector (TOYOBO).
  • the L chain gene fragment in which the L-chain variable region and constant region were linked, was inserted into the pCAGGS vector whose expression is regulated by the chicken ⁇ -actin promoter.
  • the L chain is expressed by linking the L-chain variable region of the humanized PM-1 antibody to the human kappa chain constant region via the BsiWI sequence.
  • Subclass hybrid antibodies can be produced by combining any two of the humanized PM-1 antibody H chain expression vectors carrying the constant region of human IgG1, human IgG2, or human IgG4, and coexpressing them with the humanized PM-1 antibody L-chain expression vector in cells for expression. Each antibody was expressed by the method described in Example 4-2 or the following method.
  • Human fetal renal carcinoma cell-derived HEK293H strain (Invitrogen) was suspended in a DMEM medium (Invitrogen) containing 10% Fetal Bovine Serum (Invitrogen), and this was seeded at a cell density of 5-6 x 10 5 cells/mL (10 mL per dish) in dishes used for adhesive cells (10-cm diameter, CORNING) and cultured for one day and night in a CO 2 incubator (37°C, 5% CO 2 ). Then, the medium was removed by suction, and 6.9 mL of CHO-S-SFM-II (Invitrogen) medium was added. As described below, the mixture solutions for expressing the different subclass antibodies and the mixture solutions for expressing the hybrid antibodies (a total of 13.8 ⁇ g) were prepared using the plasmid DNAs prepared in 11-2.
  • Each mixture solution was mixed with 20.7 ⁇ L of 1 ⁇ g/mL Polyethylenimine (Polysciences Inc.) and 690 ⁇ L of CHO-S-SFMII medium, left to stand at room temperature for ten minutes, then added to the cells in each dish, and then the cells were then incubated in a CO 2 incubator (37°C, 5% CO 2 ) for four to five hours. Thereafter, 6.9 mL of CHO-S-SFM-II (Invitrogen) medium was added and then the cells were incubated in a CO 2 incubator for three days.
  • CHO-S-SFM-II Invitrogen
  • the culture supernatant was collected, then cells were removed by centrifugation (at approximately 2000 g for five minutes at room temperature), and the solution was sterilized by passing it through a 0.22 ⁇ m filter MILLEX ® -GV (Millipore). The sample was stored at 4°C until use.
  • rProtein A Sepharose TM Fast Flow 100 ⁇ L of rProtein A Sepharose TM Fast Flow (Amersham Biosciences) was added to the culture supernatant obtained by the method described in Example 11-3, and the solution was mixed by rotation at 4°C for four hours. The solution was transferred to an Ultrafree ® -MC 0.22- ⁇ m filter cup (Millipore). After three washes with 500 ⁇ L of TBS, the rProtein A Sepharose TM resin was suspended in 100 ⁇ L of 50 mM aqueous sodium acetate solution at pH 3.0, and left to stand for two minutes, and then, the antibody was eluted.
  • the eluate was immediately neutralized by adding 6.7 ⁇ L of 1.5 M Tris-HCl, 150 mM NaCl, pH 8.0.
  • the buffer of the obtained antibody solution was exchanged by dialyzing it against PBS for activity measurement, or against 20 mM acetic acid buffer containing 150 mM NaCl, pH 6.0 for DSC measurement.
  • the purified antibody carrying the H-chain constant region of human IgG1 will be referred to as "unmodified humanized anti-PM-1 antibody”
  • the antibody carrying the H-chain constant region of human IgG2 will be referred to as “IgG2-substituted humanized anti-PM-1 antibody”
  • the antibody carrying the H-chain constant region of human IgG4 will be referred to as "IgG4-substituted humanized anti-PM-1 antibody”.
  • the absorbance of the antibody-containing solution obtained in 11-4 at 280 nm was measured on ND-1000 Spectrophotometer (NanoDrop) using 2 ⁇ L of the solution, or on the DU600 spectrophotometer (BECKMAN) using 50 ⁇ L of the solution.
  • the antibody concentration was calculated from the obtained values using the following equation. PBS, or 20 mM acetic acid buffer containing 150 mM NaCl at pH6.0 was used as the blank.
  • Antibody concentration (mg/mL) absorbance x dilution factor / 14.6 x 10
  • Isoelectric focusing analysis was carried out to evaluate the alteration of surface charge as a result of substitution in the constant region.
  • PhastGel Dry IEF (Amersham Biosciences) gel was swollen for about 30 minutes in the swelling solution described below using the Phastsystem Cassette (Amersham Biosciences). 20% Glycerol 1.5 mL Pharmalyte 8-10.5 for IEF (Amersham Biosciences) 100 mL
  • Electrophoresis was performed using the swollen gel by PhastSystem (Amersham Biosciences) according to the following program. The samples were applied to the gel in Step 2. A pI calibration kit (Amersham Biosciences) was used as the pI marker. Step 1: 2000 V 2.5 mA 3.5 W 15°C 75 Vh Step 2: 200 V 2.5 mA 3.5 W 15°C 15 Vh Step 3: 2000 V 2.5 mA 3.5 W 15°C 410 Vh
  • the gel was fixed with 20% TCA, and then silver stained using a silver staining kit, protein (Amersham Biosciences) according to the protocol attached to the kit. After staining, the isoelectric points of the samples were calculated from the known isoelectric points of the pI marker.
  • the results of analysis of the unmodified, IgG2-substituted and IgG4-substituted humanized PM-1 antibodies are shown in Fig. 15 .
  • Band shifts were observed in isoelectric focusing due to subclass substitution.
  • the isoelectric points of the respective antibodies estimated in reference to the pI marker were approximately 8.9 for the IgG2-substituted humanized PM-1 antibody, and approximately 8.7 for the IgG4-substituted humanized PM-1 antibody, in contrast to approximately 9.3 for the unmodified humanized PM-1 antibody. That is, the substitution was able to provide a maximum isoelectric point difference of approximately 0.6. It was shown in this examination that the isoelectric points can be altered by substituting the constant region of an antibody subclass.
  • Fig. 16 the results of analysis of coexpressed unmodified and IgG2-substituted humanized PM-1 antibodies, and coexpressed unmodified and IgG4-substituted humanized PM-1 antibodies are shown in Fig. 16 .
  • the isoelectric points of the respective subclass hybrid antibodies estimated in reference to the pI marker were 9.2 for the unmodified humanized PM-1/IgG2-substituted human PM-1 hybrid antibody and 9.0 for the unmodified humanized PM-1/IgG4-substituted human PM-1 hybrid antibody. It was shown in this study that subclass hybrid antibodies can be produced by coexpressing a combination of expression vectors of subclass antibodies, and that the hybrid antibodies can be separated by their difference in isoelectric points.
  • Cation exchange chromatographic analysis was performed by the following method using the subclass hybrid antibodies prepared in Example 11, and the effect of the subclass substitution on separation was evaluated.
  • the conditions for cation exchange chromatographic analysis were as follows. The retention time was calculated for the unmodified humanized PM-1 antibody, the IgG2-substituted humanized PM-1 antibody, the IgG4-substituted humanized PM-1 antibody, the hybrid antibody of the unmodified humanized PM-1 antibody and IgG2-substituted humanized PM-1 antibody, and the hybrid antibody of the unmodified humanized PM-1 antibody and IgG4-substituted humanized PM-1 antibody.
  • the results of analysis of singly expressed unmodified, IgG2-substituted, and IgG4-substituted humanized PM-1 antibodies are shown in Fig. 17 .
  • the retention time of the unmodified humanized PM-1 antibody, IgG2-substituted humanized PM-1 antibody, and IgG4-substituted humanized PM-1 antibody was 60.2 minutes, 30.5 minutes, and 30.3 minutes, respectively. That is, the retention time was altered by slightly less than 30 minutes due to subclass substitution. On the other hand, the retention time was nearly the same for the IgG2-substituted humanized PM-1 antibody and the IgG4-substituted humanized PM-1 antibody, which showed a pI difference according to isoelectric focusing.
  • Fig. 18 the results of analysis of coexpressing unmodified and IgG2-substituted humanized PM-1 antibodies, and coexpressing unmodified and IgG4-substituted humanized PM-1 antibodies are shown in Fig. 18 .
  • the homodimers of each subclass and heterodimer were observed as three main peaks in the combination of the unmodified humanized PM-1 antibody and IgG2-substituted humanized PM-1 antibody, and the combination of the unmodified humanized PM-1 antibody and IgG4-substituted humanized PM-1 antibody.
  • the retention time was approximately 43.8 minutes for the unmodified humanized PM-1/IgG2-substituted humanized PM-1 hybrid antibody, and approximately 45.1 minutes for the unmodified humanized PM-1/IgG4-substituted humanized PM-1 hybrid antibody. That is, these antibodies were separated from the respective homodimers with a retention time difference of 10 minutes or more. It was shown in this examination that subclass hybrid antibodies can be produced by coexpressing a combination of expression vectors of subclass antibodies, and that the hybrid antibodies can be separated by ion exchange chromatography.
  • Example 11 The antibody solutions obtained in Example 11 were concentrated using Amicon-Ultra4 (Amicon), then enveloped in EasySep (TOMY SEIKO). After buffer exchange was performed by dialysis against 5 mM citric acid buffer (pH 6.5), subclass hybrid antibodies were purified under the following conditions.
  • Fig. 19 Peak fractions from multiple experiments were combined, concentrated using Amicon-Ultra4 (Amicon), and then enveloped in EasySep (TOMY SEIKO). The buffer was exchanged by dialysis against PBS for activity measurement, or against 20 mM acetic acid buffer containing 150 mM NaCl, pH 6.0 for DSC measurement. The fractionated peaks were reanalyzed under conditions similar to those described above and the results are shown in Fig. 20 . This shows that subclass hybrid antibodies can be fractionated and purified by ion exchange chromatography methods.
  • This technique enables separation of antibodies carrying a common H-chain variable region by using constant regions of different subclasses with different pI values.
  • bispecific antibodies can be separated by ion exchange chromatography by linking the H-chain variable regions to subclass H-chain constant regions with different pI values.
  • the pI difference between the molecules can be increased to further facilitate separation and purification by combining the above technique with the technique for introducing mutations into the variable region as shown in Example 9.
  • bispecific antibodies can be separated and purified by ion exchange chromatography by substituting the H-chain variable region with a naturally-occurring IgG subclass sequence, without worrying about antigenicity.
  • PhastGel Dry IEF (Amersham Biosciences) gel was swollen for about 30 minutes in the swelling solution described below using the Phastsystem Cassette (Amersham Biosciences). MilliQ water 1.5 mL Pharmalyte 5-8 for IEF (Amersham Biosciences) 50 ⁇ L Pharmalyte 8-10.5 for IEF (Amersham Biosciences) 50 ⁇ L
  • Electrophoresis was performed using the swollen gel by PhastSystem (Amersham Biosciences) according to the following program. The samples were applied to the gel in Step 2. A pI calibration kit (Amersham Biosciences) was used as the pI marker. Step 1: 2000 V 2.5 mA 3.5 W 15°C 75 Vh Step 2: 200 V 2.5 mA 3.5 W 15°C 15 Vh Step 3: 2000 V 2.5 mA 3.5 W 15°C 410 Vh
  • the gel was fixed with 20% TCA, and then silver stained using a silver staining kit, protein (Amersham Biosciences) according to the protocol attached to the kit.
  • Fig. 21 The results of analysis of the fractionated and purified subclass hybrid antibody products are shown in Fig. 21 . It was shown that the products can be purified without containing any subclass homodimer by using ion exchange chromatography.
  • Example 15 Activity assessment of fractionated and purified subclass hybrid antibody products 15-1. Establishment of human gp130-expressing BaF3 cell line and human gp130/human IL-6 receptor-coexpressing BaF3 cell line
  • a BaF3 cell line expressing human gp130 was established as described below.
  • the full-length human gp130 cDNA ( Hibi et al., Cell 1990; 63:1149-1157 (GenBank Accession No. NM_002184)) was amplified by PCR, and cloned into the pCOS2Zeo expression vector, from which the DHFR gene expression site of pCHOI ( Hirata et al., FEBS Letter 1994; 356:244-248 ) was removed, and to which a Zeocin resistance gene expression site was inserted, to construct pCOS2Zeo/gp130.
  • pCOS2Zeo/gp130 10 ⁇ g was mixed with BaF3 cells (0.8 x 10 7 cells) suspended in PBS, then a pulse was applied at 0.33 kV and a capacity of 950 ⁇ FD using Gene Pulser (Bio-Rad).
  • BaF3 cells subjected to the gene transfer by electroporation treatment were cultured for one day and night in RPMI1640 medium (Invitrogen) containing 0.2 ng/mL of mouse interleukin-3 (Peprotech), 10% Fetal Bovine Serum (hereinafter referred to as FBS, HyClone).
  • the cells were selected by adding RPMI1640 medium containing 100 ng/mL of human interleukin-6 (R&D), 100 ng/mL of soluble human interleukin-6 receptor (R&D systems), and 10% FBS, to establish a human gp130-expressing BaF3 cell line (hereinafter referred to as BaF3/gp130). 15-2. Assessment of the activity of fractionated and purified subclass hybrid antibody products to neutralize human IL-6
  • IL-6 neutralizing activity was evaluated using BaF3/gp130 showing IL-6-dependent growth, as described below.
  • Purified unmodified humanized PM-1 antibody, unmodified/IgG4-substituted humanized PM-1 subclass hybrid antibody, and IgG4-substituted humanized PM-1 antibody were diluted in RPMI1640 containing 10% FBS to 10 ⁇ g/mL.
  • a gene that encodes the 1st to the 344th amino acids of the soluble human IL-6 receptor ( Yamasaki et al., Science 1988; 241:825-828 (GenBank Accession No. X12830)) was introduced into CHO cells. Then, the receptor was purified from the culture supernatant. Cells were cultured for 72 hours under conditions of 37°C and 5% COz. Then, WST-8 reagent (Cell Counting Kit-8, Dojindo Laboratories) diluted two-fold with PBS was added at 20 ⁇ L/well. Immediately after, the absorbance at 450 nm (reference wavelength: 620 nm) was measured using SUNRISE CLASSIC (TECAN). After a two-hour culture, the absorbance at 450 nm (reference wavelength: 620 nm) was measured again. The IL-6 neutralizing activity was evaluated using the change in absorbance during the two-hour culture as an index.
  • the fractioned and purified unmodified humanized PM-1 antibody, unmodified/IgG4-substituted humanized PM-1 subclass hybrid antibody, and IgG4-substituted humanized PM-1 antibody had neutralizing activities equivalent to that of a purified product of humanized PM-1 antibody (bulk).
  • the subclass hybrid antibodies do not lose their original antigen-binding activities, and they function as neutralizing antibodies.
  • the isoelectric point of an antibody can be altered by only a small number of amino acid substitutions without changing its structure/function (activity). This enables efficient purification of bispecific antibodies to high purity using a standard chromatography column. The high purity allows development of the bispecific antibodies into pharmaceuticals. Thus, the methods of the present invention are highly useful for developing bispecific antibodies as pharmaceuticals.
  • Bispecific antibodies that actually have activities can be obtained efficiently by the methods of the present invention.
  • the invention further comprises the following items:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP23150077.8A 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique Pending EP4218801A3 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006097795 2006-03-31
JP2006275804 2006-10-06
EP17196942.1A EP3345616A1 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique
EP07740494.5A EP2009101B1 (fr) 2006-03-31 2007-03-30 Procede de modification d'anticorps pour purifier un anticorps bispecifique
PCT/JP2007/057058 WO2007114325A1 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP17196942.1A Division EP3345616A1 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique
EP07740494.5A Division EP2009101B1 (fr) 2006-03-31 2007-03-30 Procede de modification d'anticorps pour purifier un anticorps bispecifique

Publications (2)

Publication Number Publication Date
EP4218801A2 true EP4218801A2 (fr) 2023-08-02
EP4218801A3 EP4218801A3 (fr) 2023-08-23

Family

ID=38563592

Family Applications (3)

Application Number Title Priority Date Filing Date
EP17196942.1A Ceased EP3345616A1 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique
EP07740494.5A Active EP2009101B1 (fr) 2006-03-31 2007-03-30 Procede de modification d'anticorps pour purifier un anticorps bispecifique
EP23150077.8A Pending EP4218801A3 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP17196942.1A Ceased EP3345616A1 (fr) 2006-03-31 2007-03-30 Procédé de modification d'anticorps pour purifier un anticorps bispécifique
EP07740494.5A Active EP2009101B1 (fr) 2006-03-31 2007-03-30 Procede de modification d'anticorps pour purifier un anticorps bispecifique

Country Status (8)

Country Link
US (2) US9670269B2 (fr)
EP (3) EP3345616A1 (fr)
JP (3) JP5144499B2 (fr)
CN (1) CN105177091A (fr)
DK (1) DK2009101T3 (fr)
ES (1) ES2654040T3 (fr)
HK (1) HK1217217A1 (fr)
WO (1) WO2007114325A1 (fr)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (fr) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
CA2603264C (fr) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Substitution des anticorps de la fonction du facteur viii de coagulation sanguine
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
CA2708532C (fr) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-nr10 et son utilisation
ES2563027T3 (es) * 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
TWI682995B (zh) * 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
KR101856792B1 (ko) 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
KR101762467B1 (ko) 2010-01-29 2017-07-27 도레이 카부시키가이샤 폴리락트산계 수지 시트
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP3029066B1 (fr) 2010-07-29 2019-02-20 Xencor, Inc. Anticorps à points isoélectriques modifiés
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
EP2500073A1 (fr) 2011-03-17 2012-09-19 ChromaCon AG Procédé pour l'identification et la purification de polypeptides plurispécifiques
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
WO2013022855A1 (fr) * 2011-08-05 2013-02-14 Xencor, Inc. Anticorps avec points isoélectriques modifiés et immunofiltration
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (fr) * 2011-10-10 2013-04-18 Xencor, Inc. Procédé de purification d'anticorps
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN104011207B (zh) * 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CA2854233C (fr) 2011-11-04 2020-05-12 Zymeworks Inc. Structure d'anticorps heterodimerique stable comprenant des mutations dans le domaine fc
JP6124800B2 (ja) * 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
EP4310191A3 (fr) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène contenant une région fc modifiée
WO2014004586A1 (fr) 2012-06-25 2014-01-03 Zymeworks Inc. Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2914634B1 (fr) 2012-11-02 2017-12-06 Zymeworks Inc. Structures cristallines de domaines fc hétérodimères
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2925785A4 (fr) 2012-11-28 2016-11-16 Zymeworks Inc Paires de chaînes lourdes-chaînes légères d'immunoglobuline manipulées et leurs utilisations
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA2898100C (fr) 2013-01-14 2023-10-10 Xencor, Inc. Nouvelles proteines heterodimeres
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2970486B1 (fr) 2013-03-15 2018-05-16 Xencor, Inc. Modulation de cellules t avec des anticorps bispecifiques et des fusions fc
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2902739C (fr) * 2013-03-15 2022-11-22 Xencor, Inc. Proteines heterodimeriques
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2922950A1 (fr) 2013-09-30 2015-04-02 Shinya Ishii Procede de production d'une molecule de liaison a l'antigene dans lequel on utilise un phage auxiliaire modifie
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (fr) 2014-01-31 2019-03-27 Novartis AG Molécules d'anticorps anti-tim-3 et leurs utilisations
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3593812A3 (fr) 2014-03-15 2020-05-27 Novartis AG Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
RU2729467C2 (ru) 2014-05-28 2020-08-06 Займворкс Инк. Модифицированные антигенсвязывающие полипептидные конструкции и их применение
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
WO2016105450A2 (fr) 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
WO2016141387A1 (fr) 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
AU2016245887B2 (en) * 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
EP3288975A1 (fr) * 2015-04-29 2018-03-07 Institute for Research in Biomedicine Neutralisation ultra-puissante de cytokines par des anticorps multispécifiques et utilisations associées
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016261854B2 (en) 2015-05-12 2022-05-26 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
AU2016334063B2 (en) 2015-10-08 2023-05-25 Zymeworks Bc Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
WO2017086419A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Procédé pour renforcer la réponse immunitaire humorale
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
HK1254635A1 (zh) 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
EP3393504B1 (fr) 2015-12-22 2025-09-24 Novartis AG Récepteur antigénique chimérique (car) spécifique contre mesotheline et anticorp contre pd-l1 à utiliser combinés dans la thérapie contre le cancer
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
WO2017125897A1 (fr) 2016-01-21 2017-07-27 Novartis Ag Molécules multispécifiques ciblant cll-1
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
MY209117A (en) 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
WO2018005706A1 (fr) 2016-06-28 2018-01-04 Xencor, Inc. Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
BR112019001570A2 (pt) 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
WO2018038469A1 (fr) * 2016-08-20 2018-03-01 (주)아이벤트러스 Procédé de confirmation de production sélective d'anticorps bispécifique souhaité
KR101933656B1 (ko) * 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3523331A1 (fr) 2016-10-07 2019-08-14 Novartis AG Récepteurs antigéniques chimériques pour le traitement du cancer
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4043485A1 (fr) 2017-01-26 2022-08-17 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
EP3589647A1 (fr) 2017-02-28 2020-01-08 Novartis AG Compositions d'inhibiteur shp et utilisations pour une thérapie de récepteur d'antigène chimère
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
BR112019025612A2 (pt) 2017-06-05 2020-06-16 Janssen Biotech, Inc. Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
EP3661555B1 (fr) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Anticorps bispécifiques et leurs utilisations
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
KR20200067197A (ko) 2017-10-20 2020-06-11 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생성 방법
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
WO2019089753A2 (fr) 2017-10-31 2019-05-09 Compass Therapeutics Llc Anticorps cd137 et antagonistes pd-1 et leurs utilisations
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
AU2018361430B2 (en) * 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
TW201922291A (zh) 2017-11-16 2019-06-16 瑞士商諾華公司 組合療法
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP3737692A4 (fr) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
EP3746116A1 (fr) 2018-01-31 2020-12-09 Novartis AG Polythérapie utilisant un récepteur antigénique chimérique
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3093729A1 (fr) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anticorps diriges contre le virus de la dengue presentant une reactivite croisee au virus zika et procedes d'utilisation
WO2019195623A2 (fr) 2018-04-04 2019-10-10 Xencor, Inc. Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3784351A1 (fr) 2018-04-27 2021-03-03 Novartis AG Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
CA3099308A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions et procedes pour ameliorer la destruction de cellules cibles par des lymphocytes nk
WO2019226658A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
EP3801769A1 (fr) 2018-05-25 2021-04-14 Novartis AG Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3101019A1 (fr) 2018-06-01 2019-12-05 Compugen Ltd Anticorps bispecifiques anti-pvrig/anti-tigit et procedes d'utilisation
CA3100724A1 (fr) 2018-06-13 2019-12-19 Novartis Ag Recepteurs antigenes chimeres de la proteine de l'antigene de maturation des lymphocytes b (bcma) et utilisations connexes
CN112654394B (zh) 2018-06-19 2025-07-11 阿塔盖有限责任公司 针对补体成分5的抗体分子和其用途
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
CN112513074A (zh) 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3818083A2 (fr) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
EP3861016A2 (fr) 2018-10-03 2021-08-11 Xencor, Inc. Protéines de fusion fc hétérodimères d'il -12
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
IL284317B2 (en) 2018-12-24 2025-10-01 Sanofi Sa Multispecific binding pseudo-fab proteins
WO2020159918A2 (fr) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Anticorps bispécifiques et leurs utilisations
MX2021009769A (es) * 2019-02-14 2021-09-08 Merus Nv Produccion de composiciones que comprenden dos o mas anticuerpos.
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (fr) 2019-02-15 2024-04-03 Novartis AG Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020172553A1 (fr) 2019-02-22 2020-08-27 Novartis Ag Polythérapies à base de récepteurs d'antigènes chimériques egfrviii et d'inhibiteurs de pd -1
UA128825C2 (uk) 2019-03-01 2024-10-30 Ксенкор, Інк. Гетеродимерні антитіла, що зв'язують enpp3 та cd3
KR20220029546A (ko) 2019-03-29 2022-03-08 아타르가, 엘엘씨 항 fgf23 항체
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
AR122263A1 (es) * 2019-05-09 2022-08-31 Genentech Inc Métodos para producir anticuerpos
JPWO2020246563A1 (fr) 2019-06-05 2020-12-10
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
IL292594A (en) * 2019-11-07 2022-07-01 Amgen Inc Training with a high salt load in cation exchange chromatography to remove impurities associated with the product
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
CN115298322A (zh) 2020-01-17 2022-11-04 贝克顿迪金森公司 用于单细胞分泌组学的方法和组合物
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
CN115380210A (zh) * 2020-04-02 2022-11-22 中外制药株式会社 含多特异性抗原结合分子的组合物中的杂质分子的分析方法
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
JP2020162622A (ja) * 2020-06-25 2020-10-08 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (fr) 2020-07-28 2022-02-03 Celltas Bio, Inc. Molécules d'anticorps contre le coronavirus et leurs utilisations
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3192204A1 (fr) 2020-08-19 2022-02-24 Xencor, Inc. Anticorps anti-cd28 et/ou compositions anti-b7h3
JP7731359B2 (ja) 2020-08-28 2025-08-29 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
WO2022162569A1 (fr) 2021-01-29 2022-08-04 Novartis Ag Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
AU2022299846B2 (en) 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
TWI864408B (zh) 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
EP4405396A2 (fr) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
JPWO2023053282A1 (fr) 2021-09-29 2023-04-06
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023150778A1 (fr) 2022-02-07 2023-08-10 Visterra, Inc. Molécules d'anticorps anti-idiotype et leurs utilisations
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023220695A2 (fr) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer her2 positif
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
CN120265651A (zh) 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
WO2024168061A2 (fr) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Molécules d'anticorps se liant au sars-cov-2
WO2025090753A1 (fr) * 2023-10-26 2025-05-01 Amgen Inc. Exploitation de propriétés d'anticorps natifs pour guider une sélection bispécifique
WO2025122634A1 (fr) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025157168A1 (fr) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Focalisation isoélectrique capillaire imagée pour détecter un sous-produit de mésappariement dans des anticorps bispécifiques asymétriques
WO2025249551A1 (fr) * 2024-05-31 2025-12-04 中外製薬株式会社 Méthode permettant de quantifier le mésappariement de l'échange de chaînes légères d'un anticorps bispécifique
WO2026036047A1 (fr) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Molécules d'anticorps se liant à fixa et fx et leurs utilisations
WO2026058155A1 (fr) 2024-09-11 2026-03-19 Novartis Ag Anticorps ciblant il-31

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
JPH0159878B2 (fr) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
WO1992019759A1 (fr) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
WO1993019172A1 (fr) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
WO1995001438A1 (fr) 1993-06-30 1995-01-12 Medical Research Council Membres d'une paire de liaison specifique dont une fraction chimique est liee par covalence dans le site de liaison; production et selection de ces membres
WO1995015388A1 (fr) 1993-12-03 1995-06-08 Medical Research Council Proteines et peptides de liaison recombines
WO1995015393A1 (fr) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau vecteur de detection d'expression
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
WO1998013388A1 (fr) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps contre les peptides lies a la parathormone humaine
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999051743A1 (fr) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises
JP2005112514A (ja) 2003-10-06 2005-04-28 Tadano Ltd 伸縮ブーム

Family Cites Families (328)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5144499B1 (fr) 1970-08-29 1976-11-29
JPS5334319B2 (fr) 1971-12-28 1978-09-20
JPS5717624B2 (fr) 1974-04-17 1982-04-12
JPS59878B2 (ja) 1975-09-04 1984-01-09 松下電工株式会社 感知器
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
JPH0234615Y2 (fr) 1986-08-08 1990-09-18
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
WO1991008770A1 (fr) 1989-12-11 1991-06-27 Immunomedics, Inc. Procede de ciblage par anticorps d'agents diagnostiques ou therapeutiques
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
TW212184B (fr) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994013806A1 (fr) 1992-12-11 1994-06-23 The Dow Chemical Company Anticorps monocatenaires multivalents
AU7214294A (en) 1993-07-01 1995-01-24 Dade International Inc. Process for the preparation of factor x depleted plasma
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
DE4419399C1 (de) * 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU702250B2 (en) 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
JP3590070B2 (ja) 1995-02-28 2004-11-17 ザ プロクター アンド ギャンブル カンパニー 優れた微生物安定性を有する無炭酸飲料製品の製造
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU5509296A (en) 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
ATE307887T1 (de) 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
FR2745008A1 (fr) 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
US5945231A (en) * 1996-03-26 1999-08-31 California Institute Of Technology Direct liquid-feed fuel cell with membrane electrolyte and manufacturing thereof
JP3032287U (ja) 1996-06-10 1996-12-17 幸喜 高橋 人 形
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
IL127872A0 (en) 1996-07-19 1999-10-28 Amgen Inc Analogs of cationic proteins
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6323000B2 (en) 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
EP0970227B1 (fr) 1997-03-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Anticorps de recombinaison et immunoconjugues cibles sur des cellules et tumeurs servant de support a cd-22
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP3992298B2 (ja) 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
DK1074268T3 (da) 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
WO2000018806A1 (fr) 1998-09-25 2000-04-06 Horst Lindhofer Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US7286585B2 (en) * 1998-12-21 2007-10-23 Finisar Corporation Low temperature grown layers with migration enhanced epitaxy adjacent to an InGaAsN(Sb) based active region
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
CA2390662A1 (fr) 1999-12-14 2001-06-21 The Burnham Institute Polypeptides bcl-g, acides nucleique de codage et leurs procedes d'utilisation
WO2001064713A2 (fr) 2000-03-01 2001-09-07 Christoph Gasche Variants du recepteur d'interleukine-10 (il-10) des mammiferes
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
DK1265914T3 (da) 2000-03-22 2008-03-10 Curagen Corp WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
JP2004505609A (ja) * 2000-04-03 2004-02-26 オックスフォード　グリコサイエンシズ（ユーケー）　リミテッド 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
WO2001079494A1 (fr) 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
CZ20023913A3 (cs) 2000-05-03 2003-09-17 Munich Biotech Ag Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
EP1299419A2 (fr) 2000-05-24 2003-04-09 Imclone Systems, Inc. Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
CA2411102A1 (fr) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
SG136804A1 (en) 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
JP4908721B2 (ja) 2000-07-17 2012-04-04 中外製薬株式会社 生理活性を有するリガンドのスクリーニング方法
CA2422076A1 (fr) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002033072A1 (fr) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps degrade, agoniste de tpo
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
EP2351838A1 (fr) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistiques qui réticuler
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
CA2451493C (fr) 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de croissance cellulaire renfermant un anticorps anti-glypicane 3
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
PL374495A1 (en) 2001-10-15 2005-10-31 Immunomedics, Inc. Direct targeting binding proteins
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
EP1573002A4 (fr) 2002-02-11 2008-07-16 Genentech Inc Variantes d'anticorps a vitesses d'association d'antigene accelerees
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1500665B1 (fr) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha PROCEDES D'ELABORATION DES BANQUES scDb
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
WO2005056606A2 (fr) 2003-12-03 2005-06-23 Xencor, Inc Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2003107218A1 (fr) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Dispositif de prediction d'interactions
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
WO2003104425A2 (fr) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nouveaux anticorps anti-cd22 stables
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
EP1541165A4 (fr) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Methode de stabilisation de preparations de solution de proteines
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8158385B2 (en) 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0224082D0 (en) * 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
WO2004065611A1 (fr) 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha Procede de selection par criblage d'une chaine legere d'anticorps
CA2515081A1 (fr) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1616880A4 (fr) 2003-03-13 2006-07-26 Chugai Pharmaceutical Co Ltd Ligand a activite agoniste vis-a-vis d'un recepteur ayant subi une mutation
EP1609803A4 (fr) 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd Anticorps modifie dirige contre cd22 et son utilisation
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2408582T3 (es) * 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
EP1636264A2 (fr) 2003-06-24 2006-03-22 MERCK PATENT GmbH Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite
EP1644416A4 (fr) 2003-06-30 2007-08-29 Centocor Inc Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (fr) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
JPWO2005056602A1 (ja) 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530266A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056605A1 (fr) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Anticorps modifies reconnaissant un recepteur trimere ou plus grand
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
CN1330448C (zh) * 2004-02-25 2007-08-08 苏州宝时得电动工具有限公司 往复式电动工具的往复杆平衡机构
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005112564A2 (fr) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation
TW200605906A (en) 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
CN1842540B (zh) 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1789446A2 (fr) * 2004-09-02 2007-05-30 Genentech, Inc. Molecules heteromultimeriques
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1810035A4 (fr) 2004-11-10 2010-03-17 Macrogenics Inc Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
JP5787461B2 (ja) 2004-12-14 2015-09-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 免疫グロブリンの精製方法
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
EP1829961A4 (fr) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Procede de preparation d'un anticorps a l'aide d'une cellule dont la fonction de transporteur du fucose est inhibee
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
WO2006076594A2 (fr) 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
JP4986633B2 (ja) 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
CA2602663A1 (fr) 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
CA2603264C (fr) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Substitution des anticorps de la fonction du facteur viii de coagulation sanguine
SG161281A1 (en) 2005-04-15 2010-05-27 Genentech Inc Hgf beta chain variants
WO2006116260A2 (fr) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
CA2607281C (fr) 2005-05-05 2023-10-03 Duke University Traitements des maladies auto-immunes par anticorps anti-cd19
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
JP5224580B2 (ja) 2005-06-10 2013-07-03 中外製薬株式会社 ｓｃ（Ｆｖ）２部位特異的変異体
EP1893647A2 (fr) * 2005-06-23 2008-03-05 MedImmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
US20070036786A1 (en) 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
JP2009510102A (ja) 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
WO2007060411A1 (fr) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CA2644663A1 (fr) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Anticorps agoniste dirige contre le recepteur de la thrombopoietine humaine
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP2025346B1 (fr) 2006-04-07 2016-08-10 Osaka University Promoteur de régénération musculaire
JP2009539841A (ja) 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
WO2007142325A1 (fr) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha Prévention ou traitement d'une maladie inflammatoire
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008090960A1 (fr) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. Composition d'anticorps génétiquement recombinés capable de se lier spécifiquement au ganglioside gm2
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
WO2008119353A1 (fr) 2007-03-29 2008-10-09 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EP2155790A1 (fr) 2007-05-31 2010-02-24 Genmab A/S Procédé d'extension de la demi-vie de molécules exogènes ou endogènes solubles
US20100221252A1 (en) 2007-06-29 2010-09-02 Schering Corporation Mdl-1 uses
EP2031064A1 (fr) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé d'augmentation de titres de protéines
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009041734A1 (fr) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Anticorps agoniste anti-récepteur de la thrombopoïétine humaine
EP2206775B1 (fr) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps du récepteur anti-il-6
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
CA2708532C (fr) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-nr10 et son utilisation
KR101672271B1 (ko) 2007-12-18 2016-11-03 바이오얼라이언스 씨.브이. 암세포에서 발현된 ｃｄ-43 및 ｃｅａ 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
WO2009120922A2 (fr) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
CA2722600C (fr) 2008-05-01 2014-01-21 Amgen Inc. Anticorps anti-hepcidine et methodes d'utilisation associees
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064090A1 (fr) 2008-12-02 2010-06-10 Pierre Fabre Medicament Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
EP2389192A4 (fr) 2009-01-23 2013-01-16 Biogen Idec Inc Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
EP2403531A4 (fr) 2009-03-05 2013-02-27 Abbott Lab Protéines de liaison à il-17
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2010107110A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
WO2010120561A1 (fr) 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
KR101856792B1 (ko) 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
CA2787755A1 (fr) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation par des anticorps anti-ilt5 et fragments d'anticorps se liant a ilt5
CA2787783A1 (fr) 2010-01-20 2011-07-28 Tolerx, Inc. Anticorps anti-ilt5 et fragments d'anticorps se liant a ilt5
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
JP5998050B2 (ja) 2010-03-31 2016-09-28 Jsr株式会社 アフィニティークロマトグラフィー用充填剤
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
EP3029066B1 (fr) 2010-07-29 2019-02-20 Xencor, Inc. Anticorps à points isoélectriques modifiés
CA2808154A1 (fr) 2010-08-13 2012-02-16 Medimmmune Limited Polypeptides monomeres comprenant des regions du variant fc et procedes d'utilisation de ceux-ci
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US20140112883A1 (en) 2011-04-20 2014-04-24 Liquidating Trust Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CA2854233C (fr) 2011-11-04 2020-05-12 Zymeworks Inc. Structure d'anticorps heterodimerique stable comprenant des mutations dans le domaine fc
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
ES2564281T3 (es) 2012-03-08 2016-03-21 F. Hoffmann-La Roche Ag Formulación de anticuerpos Abeta
PT2825559T (pt) 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP2914634B1 (fr) 2012-11-02 2017-12-06 Zymeworks Inc. Structures cristallines de domaines fc hétérodimères
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
JP6630036B2 (ja) 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2978038A1 (fr) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Polytherapie avec des facteurs de coagulation et des anticorps polyspecifiques
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0159878B2 (fr) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
WO1992019759A1 (fr) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
WO1993019172A1 (fr) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
WO1995001438A1 (fr) 1993-06-30 1995-01-12 Medical Research Council Membres d'une paire de liaison specifique dont une fraction chimique est liee par covalence dans le site de liaison; production et selection de ces membres
WO1995015388A1 (fr) 1993-12-03 1995-06-08 Medical Research Council Proteines et peptides de liaison recombines
WO1995015393A1 (fr) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau vecteur de detection d'expression
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
WO1998013388A1 (fr) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps contre les peptides lies a la parathormone humaine
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999051743A1 (fr) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises
JP2005112514A (ja) 2003-10-06 2005-04-28 Tadano Ltd 伸縮ブーム

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
"A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS, article "Strategies for Protein Purification and Characterization"
"GenBank", Database accession no. NM_002184
A KOHLERC. MILSTEIN, METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
AMIT ET AL., SCIENCE, vol. 233, 1986, pages 747 - 53
ATWELL ET AL., MOL.IMMUNOL., vol. 33, 1996, pages 1301 - 12
BIRDWALKER, TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 7
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
CANCER RESEARCH, vol. 60, 2000, pages 4336 - 41
CARTER P: "Bispecific human IgG by design", J. IMMUNOL. METHODS., vol. 248, no. 1-2, February 2001 (2001-02-01), pages 7 - 15, XP002974199, DOI: 10.1016/S0022-1759(00)00339-2
CHO, J. EXP. MED., vol. 108, 1995, pages 945
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 17
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 8
CO ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 76
COX K.M. ET AL., NAT. BIOTECHNOL., vol. 24, no. 12, December 2006 (2006-12-01), pages 1591 - 1597
CURR. OPIN. DRUG DISCOV. DEVEL., vol. 9, no. 2, 2006, pages 184 - 93
DALL'ACQUA WF, METHODS, vol. 36, no. 1, May 2005 (2005-05-01), pages 43 - 60
EBERT ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
GRIFFITHS ET AL., EMBO J., vol. 113, 1994, pages 3245 - 315
GUPTA SSURESH M: "Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates", J. BIOCHEM. BIOPHYS. METHODS., vol. 51, no. 3, 31 May 2002 (2002-05-31), pages 203 - 16, XP002705274, DOI: 10.1016/S0165-022X(01)00231-7
HIBI ET AL., CELL, vol. 63, 1990, pages 1149 - 1157
HIRATA ET AL., FEBS LETTER, vol. 356, 1994, pages 244 - 248
HOLLIGER ET AL., PROTEIN ENGINEERING, vol. 9, 1996, pages 299 - 305
HUDSON ET AL., J IMMUNOL. METHODS, vol. 231, 1999, pages 177 - 89
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 83
IMMUNOL. METHOD., vol. 179, 1995, pages 203 - 214
JOHN ET AL., PROTEIN ENGINEERING, vol. 12, no. 7, 1999, pages 597 - 604
JOHNSON ET AL., METHOD IN ENZYMOLOGY, vol. 203, 1991, pages 88 - 98
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 231, 1999, pages 177 - 89
KABAT EA ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH
KIPPS ET AL., J. CLIN. INVEST., vol. 87, 1991, pages 2087 - 2096
KREUTZ FT ET AL.: "Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography.", J. CHROMATOGR. B. BIOMED. SCI. APPL., vol. 714, no. 2, 4 September 1998 (1998-09-04), pages 161 - 70, XP004146952, DOI: 10.1016/S0378-4347(98)00180-7
KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488
LINDHOFER H ET AL.: "Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.", J. IMMUNOL., vol. 155, no. 1, 1 July 1995 (1995-07-01), pages 219 - 25, XP002190775
MA ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 131 - 138
MANZKE O ET AL.: "Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography", J. IMMUNOL. METHODS., vol. 208, no. 1, 13 October 1997 (1997-10-13), pages 65 - 73, XP002306760
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 97
MARVIN JSZHU Z: "Recombinant approaches to IgG-like bispecific antibodies.", ACTA. PHARMACOL. SIN., vol. 26, no. 6, June 2005 (2005-06-01), pages 649 - 58
MENDEZ ET AL., NAT. GENET., vol. 15, 1997, pages 146 - 56
MERCHANT AM ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 677 - 681
MERCHANT AM ET AL.: "An efficient route to human bispecific IgG", NAT. BIOTECHNOL., vol. 16, no. 7, July 1998 (1998-07-01), pages 677 - 81, XP002141015, DOI: 10.1038/nbt0798-677
MOL. CELL BIOL., vol. 8, 1998, pages 466 - 472
MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 24, 1992, pages 107 - 17
NIWA ET AL., GENE, vol. 108, 1991, pages 193 - 200
ONO K. ET AL., MOL. IMMUNOL., vol. 36, no. 6, April 1999 (1999-04-01), pages 387 - 395
ORITA ET AL., BLOOD, vol. 105, 2005, pages 562 - 566
P. HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
PERISIC ET AL., STRUCTURE, vol. 113, 1994, pages 1217 - 315
PLUCKTHUNSKERRA, METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
ROUSSEAUX ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 63
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
SATO, K. ET AL., CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
SEGAL D. M. ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 11, 1999, pages 558 - 562
SUSUMU ET AL., NATURE, vol. 315, 1985, pages 592 - 594
VALLE ET AL., NATURE, vol. 291, 1981, pages 338 - 340
VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 14
VICKI GLASER, SPECTRUM BIOTECHNOLOGY APPLICATIONS, 1993
WATERHOUSES ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 2265 - 6
YAMASAKI ET AL., SCIENCE, vol. 241, 1988, pages 825 - 828

Also Published As

Publication number Publication date
JPWO2007114325A1 (ja) 2009-08-20
JP2013078313A (ja) 2013-05-02
WO2007114325A1 (fr) 2007-10-11
JP6055271B2 (ja) 2016-12-27
US9670269B2 (en) 2017-06-06
HK1217217A1 (zh) 2016-12-30
EP2009101A1 (fr) 2008-12-31
EP2009101A4 (fr) 2009-10-21
EP4218801A3 (fr) 2023-08-23
EP2009101B1 (fr) 2017-10-25
DK2009101T3 (en) 2018-01-15
JP6219877B2 (ja) 2017-10-25
JP2015146822A (ja) 2015-08-20
US20170283483A1 (en) 2017-10-05
JP5144499B2 (ja) 2013-02-13
EP3345616A1 (fr) 2018-07-11
US20090263392A1 (en) 2009-10-22
US10934344B2 (en) 2021-03-02
CN105177091A (zh) 2015-12-23
ES2654040T3 (es) 2018-02-12

Similar Documents

Publication Publication Date Title
US10934344B2 (en) Methods of modifying antibodies for purification of bispecific antibodies
US20260035728A1 (en) Methods for producing polypeptides by regulating polypeptide association
US12473375B2 (en) Methods for controlling blood pharmacokinetics of antibodies
CN101460622A (zh) 用于纯化双特异性抗体的抗体修饰方法
HK1129420A (en) Antibody modification method for purifying bispecific antibody
HK1208229B (zh) 调控抗体血液动力学的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 2009101

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3345616

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/02 20060101ALI20230720BHEP

Ipc: C12N 5/10 20060101ALI20230720BHEP

Ipc: C12N 15/09 20060101ALI20230720BHEP

Ipc: C12N 1/21 20060101ALI20230720BHEP

Ipc: C12N 1/19 20060101ALI20230720BHEP

Ipc: C12N 1/15 20060101ALI20230720BHEP

Ipc: C07K 19/00 20060101ALI20230720BHEP

Ipc: C07K 16/00 20060101ALI20230720BHEP

Ipc: A61P 43/00 20060101ALI20230720BHEP

Ipc: A61K 39/00 20060101AFI20230720BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240216

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240423